

PCT

INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>C12P 1/00, C12N 15/67</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/10089</b> <b>(43) International Publication Date:</b> 12 March 1998 (12.03.98)
<b>(21) International Application Number:</b> PCT/DK97/00373 <b>(22) International Filing Date:</b> 8 September 1997 (08.09.97) <b>(30) Priority Data:</b> 0963/96 6 September 1996 (06.09.96) DK <b>(71)(72) Applicant and Inventor:</b> JENSEN, Peter, Ruhdal [DK/DK]; Søgårdsvej 19, DK-2820 Gentofte (DK). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> SNOEP, Jacky, Leender [NL/NL]; Joubert Straat 5 A, NL-1091 XM Amsterdam (NL); WESTERHOFF, Hans, Victor [NL/NL]; Charlie Parker Straat 25, NL-1066 CX Amsterdam (NL). <b>(74) Agent:</b> HOFMAN-BANG & BOUTARD, LEHMANN & REE A/S; Hans Bekkevolds Allé 7, DK-2900 Hellerup (DK).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> A METHOD OF IMPROVING THE PRODUCTION OF BIOMASS OR A DESIRED PRODUCT FROM A CELL  <b>(57) Abstract</b>  The production of biomass or a desired product from a cell can be improved by inducing conversion of ATP to ADP without primary effects on other cellular metabolites or functions which is achieved by expressing an uncoupled ATPase activity in said cell and incubating the cell with a suitable substrate to produce said biomass or product. This is conveniently done by expressing in said cell the soluble part (F <sub>1</sub> ) of the membrane bound (F <sub>0</sub> F <sub>1</sub> type) H <sup>+</sup> -ATPase or a portion of F <sub>1</sub> exhibiting ATPase activity. The organism from which the F <sub>1</sub> ATPase or portions thereof is derived, or in which the F <sub>1</sub> ATPase or portions thereof is expressed, may be selected from prokaryotes and eukaryotes. In particular the DNA encoding F <sub>1</sub> or a portion thereof may be derived from bacteria and eukaryotic microorganisms such as yeasts, other fungi and cell lines of higher organisms and be selected from the group consisting of the gene encoding the F <sub>1</sub> subunit β or a portion thereof and various combinations of said gene or portion with the genes encoding the other F <sub>1</sub> subunits or portions thereof. The method can be used i.a. for optimizing the formation of biomass or a desired product by a cell by expressing different levels of uncoupled ATPase activity in the cell, incubating the cell on a suitable substrate, measuring the conversion rate of substrate into biomass or the desired product at each level of ATPase expression, and choosing a level of ATPase expression at which the conversion rate is optimized.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

A method of improving the production of biomass or a desired product from a cell

This invention relates to a method of improving the production of biomass or a desired product from a cell by inducing conversion of ATP to ADP without primary effects on other cellular metabolites or functions. The invention also relates to a method of optimizing the production of biomass or a desired product from a cell utilizing this first method. The desired product may for example be lactic acid produced by lactic acid bacteria and ethanol or carbondioxide produced by yeast.

**BACKGROUND OF THE INVENTION**

A wide range of microorganisms are used for the production of various organic compounds and heterologous proteins. One example hereof is the production of lactic acid and other organic compounds by the lactic acid group of bacteria, which results in the acidification and flavouring of dairy products, better known as cheese and yougurt production.

From the microorganism's point of view, the organic compounds which are excreted from the cells are often merely the by-product of a process that is vital to the cells: the production of various forms of free energy (ATP, NAD(P)H, membrane potential, etc.). Therefore, although many of the microorganisms which are being employed in these processes are reasonably well suited for the purpose, there is still a great potential for optimizing the productivity of these organisms when looking from the bioreactor point of vue. Likewise, the production of heterologous proteins by a microorganism is not what the organism was adapted for and also here there is a potential for optimization.

Often when microorganisms are engineered for the purpose of optimizing an industrial production process, the reactions leading to the desired product will affect the delicate balance of co-factors involved in the energy metabolism of the cell. For instance if the glycolytic reactions producing lactate from sugar were somehow to be enhanced (e.g. by overexpressing the glycolytic enzymes) this would automatically lead to the conversion of ADP to ATP. The ratio between the concentrations of ATP and ADP is usually quite high in the growing cell ( $[ATP]/[ADP] > 10$ ), and when the ratio  $[ATP]/[ADP]$  changes, the sum of  $[ATP]$  and  $[ADP]$  still remains virtually constant. Therefore, if in the example above, the enhanced production of ATP changes the  $[ATP]/[ADP]$  ratio from 10 to say 30, this will only marginally affect the concentration of ATP. The ADP concentration however will change by a factor of three. The cells will then hardly feel the surplus of ATP but the ADP pool in the cells may be depleted to such an extent that reactions in which ADP is a co-factor or allosteric regulator will be suppressed by the lack of ADP. The result may be that the total flux through the pathway (here through glycolysis) is only marginally increased. In the future, this situation is likely to occur more frequently, as the productivity of bioreactors are optimized by other means, and in these cases, it will be even more important (compared to the normal cell) to regenerate the ADP from ATP, in order to further increase the productivity.

Previously, attempts have been made to decrease the intracellular ATP concentration in yeast, employing sets of reactions which together form futile cycles, see EP patent No. 245 481. Often, the first reaction of a futile cycle is part of the regular metabolic network of the cell, for instance the phosphorylation of a glycolytic intermediate, coupled to the utilisation of ATP. The second reaction, which may also sometimes be part of the

metabolic network, then de-phosphorylates the glycolytic intermediate without regenerating the ATP that was consumed in the first process, the overall effect being that a high energy phosphate bond is consumed. The limited success that this strategy has had so far, is probably due to the fact that it is impossible to obtain a significant futile flux without decreasing the concentration of the phosphorylated intermediate, thereby disturbing the cellular function and ultimately the growth. In addition, when the approach is to decrease the concentration of a glycolytic intermediate, this will effectively remove the substrate for the remaining part of the glycolysis, which will often result in a decreased flux through this pathway, rather than the desired increased flux.

Other strategies have been to use chemicals such as dinitrophosphate to stimulate the activity of the plasma membrane  $H^+$ -ATPase by the addition of uncouplers of the membrane potential, or to genetically express the enzyme acid phosphatase in the cytoplasm, an enzyme that will remove phosphate groups from organic metabolites and proteins. However, both of these approaches suffer from the same inherent problem: they are unspecific and a range of cellular reactions/concentrations may be affected. For instance, the acid phosphatase will remove phosphate groups from essential metabolites and proteins, thus disturbing various metabolic fluxes and metabolic regulation. The uncoupling of the plasma membrane  $H^+$ -ATPase will disturb the intracellular pH in addition to the gradient of numerous ions across the cytoplasmic membrane. Besides, the addition of chemicals such as dinitrophosphate is undesirable for most purposes.

#### SUMMARY OF THE INVENTION

The idea of the invention is to use a highly specific and clean way to increase the intracellular level of ADP,

which does not suffer from the limitations described above: to express in a well-controlled manner an enzyme that has ATP-hydrolytic activity in the living cell without producing other products and without coupling this activity to energy conservation. Such an enzymatic activity is of course not likely to be found in a normal cell, because the cell would then lose some of its vital energy reservoir.

Accordingly the present invention provides a method of improving the production of biomass or a desired product from a cell, the method being characterized by expressing an uncoupled ATPase activity in said cell to induce conversion of ATP to ADP without primary effects on other cellular metabolites or functions, and incubating the cell with a suitable substrate to produce said biomass or product.

One of the normal enzymes that comes closest to the ideal ATP-hydrolyzing enzyme, is the membrane bound  $H^+$ -ATPase. This huge enzyme complex consists of two parts, the membrane integral part ( $F_0$ ) and the cytoplasmic part ( $F_1$ ). Together the two parts couples the hydrolysis of ATP to ADP and inorganic phosphate ( $P_i$ ), to translocation of protons across the cytoplasmic membrane, or *vice versa*, using the proton gradient to drive ATP synthesis from ADP and  $P_i$ .

The method of the invention is conveniently carried out by expressing in said cell the soluble part ( $F_1$ ) of the membrane bound ( $F_0F_1$  type)  $H^+$ -ATPase or a portion of the  $F_1$  exhibiting ATPase activity.

The membrane bound  $H^+$ -ATPase complex is found in similar form in prokaryotic as well as eukaryotic organisms, and thus  $F_1$  and portions thereof expressing ATPase activity

can be expressed in both prokaryotic and eukaryotic cells.

5 The organism from which the F<sub>1</sub> ATPase or portions thereof is derived, or in which the F<sub>1</sub> ATPase or portions thereof is expressed, may be selected from prokaryotes and eukaryotes, in particular from bacteria and eukaryotic microorganisms such as yeasts, other fungi and cell lines of higher organisms, in particular bakers and brewers yeast.

10 A particularly interesting group of prokaryotes to which the method according to the invention can be implemented, i.e. in the dairy industry, are lactic acid bacteria of the genera *Lactococcus*, *Streptococcus*, *Enterococcus*, *Lactobacillus* and *Leuconostoc*, in particular strains of the species *Lactococcus lactis* and *Streptococcus thermophilus*. Other interesting prokaryotes are bacteria belonging to the genera *Escherichia*, *Zymomonas*, *Bacillus* and *Pseudomonas*, in particular the species *Escherichia coli*, *Zymomonas mobilis*, *Bacillus subtilis* and *Pseudomonas putida*.

25 In an expedient manner of carrying out the method according to the invention the cell is transformed or transfected with an expression vector including DNA encoding F<sub>1</sub> or a portion thereof exhibiting ATPase activity under the control of a promoter functioning in said cell, and said DNA is expressed in the cell. Said DNA encoding F<sub>1</sub> or a portion thereof may be derived from a prokaryotic or a eukaryotic organism, and it may be either homologous or heterologous to said cell.

35 The F<sub>1</sub> part of the bacterial H<sup>+</sup>-ATPase complex consists of several subunits that together are responsible for catalyzing ATP hydrolysis: the  $\beta$ -subunit is thought to carry the actual hydrolytic site for ATP hydrolysis, but

in vitro ATPase activity requires that the  $\beta$ -subunit forms a complex together with the  $\alpha$ - and  $\gamma$ -subunit ( $\alpha_3\gamma\beta_3$ ). The activity of this complex is modulated by the  $\epsilon$ -subunit, so that the in vitro activity of the  $\alpha_3\gamma\beta_3\epsilon$  complex is five fold less than the  $\alpha_3\gamma\beta_3$  complex.

In a specific embodiment of the method according to the invention said DNA encoding F<sub>1</sub> or a catalytic active portion thereof, is derived from *Escherichia coli*, *Streptococcus thermophilus* or *Lactococcus lactis* and is selected from the group consisting of the gene encoding the F<sub>1</sub> subunit  $\beta$  or a catalytically active portion thereof and various combinations of said gene or portion with the genes encoding the F<sub>1</sub> subunits  $\delta$ ,  $\alpha$ ,  $\gamma$  and  $\epsilon$  or catalytically active portions thereof.

In particular said DNA encoding F<sub>1</sub> or a portion thereof may be selected from the group consisting of the *Escherichia coli*, *Streptococcus thermophilus* and *Lactococcus lactis* genes *atpHAGDC* (coding for subunits  $\delta$ ,  $\alpha$ ,  $\gamma$ ,  $\beta$ ,  $\epsilon$ ), *atpAGDC* (coding for subunits  $\alpha$ ,  $\gamma$ ,  $\beta$ ,  $\epsilon$ ), *atpAGD* (coding for subunits  $\alpha$ ,  $\gamma$ ,  $\beta$ ), *atpDC* (coding for subunits  $\beta$ ,  $\epsilon$ ) and *atpD* (coding for subunit  $\beta$  alone).

Particularly interesting eukaryotes are the yeasts *Saccharomyces cerevisiae*, *Phaffia rhodozyma* or *Trichoderma reesei*, and the DNA encoding F<sub>1</sub> or a portion thereof may be derived from such organisms and is selected from the group consisting of the gene encoding the F<sub>1</sub> subunit  $\beta$  or a portion thereof and various combinations of said gene or portion with the genes encoding the other F<sub>1</sub> subunits or portions thereof.

Vectors including DNA encoding the soluble part (F<sub>1</sub>) of the membrane bound (F<sub>0</sub>F<sub>1</sub> type) H<sup>+</sup>-ATPase or a portion of F<sub>1</sub> exhibiting ATPase activity, derived from the lactic acid bacteria *Lactococcus lactis* and *Streptococcus ther-*



*mophilus* and from the yeasts *Saccharomyces cerevisiae*, *Phaffia rhodozyma* or *Trichoderma reesei* are also comprised by the invention as well as expression vectors including such DNA under the control of a promoter capable  
5 of directing the expression of said DNA in a prokaryotic or eukaryotic cell.

Specific vectors according to the invention are plasmids including DNA encoding the soluble part ( $F_1$ ) of the membrane bound ( $F_0F_1$  type)  $H^+$ -ATPase or a portion of  $F_1$  exhibiting ATPase activity, said DNA being derived from  
10 *Lactococcus lactis* subsp. *cremoris* (SEQ ID No. 1), *Lactococcus lactis* subsp. *lactis* (SEQ ID No. 6), *Streptococcus thermophilus* (SEQ ID No. 10), *Phaffia rhodozyma* (SEQ ID  
15 No. 14), and *Trichoderma reesei* (SEQ ID No. 16).

Further, the invention provides a method of optimizing the formation of biomass or a desired product by a cell, the method being characterized by expressing different  
20 levels of uncoupled ATPase activity in the cell, incubating the cell on a suitable substrate, measuring the conversion rate of substrate into biomass or the desired product at each level of ATPase expression, and choosing a level of ATPase expression at which the conversion rate  
25 is optimized.

Often, but not always, the optimization of a given product flux produced by a cell will entail the attainment of either maximum or minimum conversion rate of a substrate.  
30

In an expedient manner of practicing this method of the invention a number of specimens of said cell are transformed or transfected with their respective expression vector each including DNA encoding a different portion of  
35 the cytoplasmic part ( $F_1$ ) of the membrane bound ( $F_0F_1$  type)  $H^+$ -ATPase up to and including the entire  $F_1$ , each portion exhibiting ATPase activity, said DNA in each ex-

pression vector being under the control of a promoter functioning in said cell, incubating each cell specimen on a suitable substrate, measuring the conversion rate of substrate into biomass or the desired product in each specimen, and choosing a specimen yielding an optimal conversion rate. In a particular embodiment of this manner, which is especially suited for scientific studies, the promoter in each expression vector is an inducible promoter, and each cell specimen is grown at different concentrations of inducer in order to fine-tune the optimal conversion rate.

In a preferred manner of practicing the above method of optimizing the performance of a cell a number of specimens of said cell are transformed or transfected with their respective expression vector including DNA encoding a portion of the cytoplasmic part ( $F_1$ ) of the membrane bound ( $F_0F_1$  type)  $H^+$ -ATPase up to and including the entire  $F_1$ , said portion exhibiting ATPase activity, said DNA in the respective expression vectors being under the control of each of a series of promoters covering a broad range of promoter activities and functioning in said cell, incubating each cell specimen on a suitable substrate, measuring the conversion rate of substrate into biomass or the desired product by each specimen, and choosing a specimen yielding an optimal conversion rate. In a more preferred embodiment of this manner, which is well suited to establish an optimal production strain, the respective expression vectors include DNA encoding different such portions of  $F_1$  up to and including the entire  $F_1$ , each DNA in respective expression vectors being under the control of each of a series of promoters covering a broad range of promoter activities and functioning in said cell.

Also in this method of the invention the DNA encoding a portion of  $F_1$  up to and including the entire  $F_1$  may be

derived from a prokaryotic or a eukaryotic organism, and it may be either homologous or heterologous to said organism. The specific DNAs mentioned above may also conveniently be employed in this method.

5

#### BRIEF DESCRIPTION OF THE DRAWINGS

**Figure 1.** A linear representation of the plasmids constructed for modulating the cellular [ATP]/[ADP] ratio in *E. coli* (not drawn to scale).

10

**Figure 2.** Effect of induction of F<sub>1</sub>-ATPase activity on the growth of *E. coli* in batch culture. Cells were grown for more than 10 generations in minimal medium supplemented with glucose (0.4 g/l), ampicillin (0.1 g/l) and the indicated concentration of inducer, IPTG.

15

**Figure 3.** Effect of ATPase expression on the intracellular concentration of ATP and ADP (concentration in arbitrary units), and on the ratio [ATP]/[ADP].

20

**Figure 4** Effect of increased ATPase expression on the glycolytic flux.

#### 25 DETAILED DESCRIPTION OF THE INVENTION

Many biosynthetic reactions in the living cell (anabolism), require an input of free energy (ATP), which is generated through a series of degrading reactions (catabolism). In the aerobic cell, there are two routes for ATP synthesis: 1) substrate level phosphorylation, where an energy rich phosphoryl group is transferred directly from a high energy intermediate metabolite to ADP, and 2) oxidative phosphorylation, where the free energy is first transformed into redox free energy by oxidizing the energy source, then into a proton gradient by respiration and finally the proton gradient is used by the H<sup>+</sup>-ATPase

30

35

to drive ATP synthesis from ADP and inorganic phosphate. In other cases, e.g. anaerobic growth, there is only the first route, substrate level phosphorylation, that can be used for ATP synthesis. An example hereof is the homolac-  
5 tic LAB, where lactose is converted through the glycolytic pathway to lactic acid, which is excreted from the cells and thereby lowers the pH of the growth medium (usually milk products). With respect to ATP generation, homolactic fermentation is a very inefficient process,  
10 and only four moles of ATP are produced from 1 mole of lactose through substrate level phosphorylation.

The anabolic (ATP consuming) and catabolic (ATP producing) fluxes are normally well balanced in the living  
15 cell, and therefore, in the wild-type cell under normal growth conditions, the catabolic fluxes will be proportional to the anabolic fluxes. If a reaction is introduced that for instance hydrolyzes ATP in the cell and thereby lowers the cellular energy state (i.e. the  
20  $[ATP]/[ADP]$  ratio), then either catabolism should increase or anabolism (growth) should decrease in order to make the consumption rate equal the production rate again. Which of these two scenarios will take place depends on whether, initially, the growth rate of the cell  
25 is limited through anabolism or through catabolism, i.e. whether there is a surplus or a shortage of energy in the cell to begin with. If there is a shortage of energy, then the rate of the anabolic reactions is limited by catabolism and these reactions will be sensitive to changes  
30 in the cellular energy state. Introduction of an ATP-hydrolyzing reaction is then most likely to affect the growth rate of the cells. On the other hand, if there is a surplus of energy, then the growth rate will be limited mainly by the anabolic reactions; the rate of anabolism  
35 will be insensitive to a decrease in the energy state, but the catabolic rate may increase due to a decrease in product inhibition at lower  $[ATP]/[ADP]$  ratio.

*In vitro*, the  $F_1$  part of the  $H^+$ -ATPase complex has been shown to have ATPase activity, see above. But so far nobody has managed to use the  $F_1$  complex to stimulate the glycolytic flux, or even to show that the  $F_1$  complex can hydrolyze ATP in intact cells. Indeed, when we first tried to overexpress the  $F_1$  complex, consisting of the genes for the subunits  $\alpha$ ,  $\gamma$ ,  $\beta$  and  $\epsilon$ , this had virtually no effect on the growth of *E. coli*, even when the genes were transcribed from the maximally induced *tac* promoter and on a very high copy number vector (derived from pUC18). One skilled in the art of gene expression in *E. coli* will appreciate that this combination is one of the most efficient expression systems that exists for this organism.

We then decided to try to express different combinations of subunits of the  $F_1$  complex, in order to see if other combinations of subunits would be more powerful. Plasmids were constructed containing various combinations of the genes encoding the  $F_1$  part of the bacterial  $F_1F_0$ -ATPase complex from *E. coli*. The genes were expressed, either from an inducible (*lac*-type) promoter at various concentrations of inducer or from a series of constitutive promoters of varying promoter activity. These plasmids should express various levels of ATPase activity when introduced into the bacterial cell. Depending on which  $F_1$  genes are present on the plasmid and the strength of the promoter which is used to drive the expression, we observed various degrees of inhibition of the growth of the cells harbouring these plasmids. Surprisingly, the beta subunit alone and in combination with the epsilon subunit turned out to be far more active *in vivo* than the entire  $F_1$  complex.

The objective of this work was to affect the energy state of the cells, as reflected in the ratio  $[ATP]/[ADP]$ . We therefore measured the intracellular concentration of ATP

and ADP in growing cells expressing various activities of F<sub>1</sub>-ATPase. Indeed the ATP concentration decreased slightly with increasing ATPase activity and the ADP concentration increased, and therefore the [ATP]/[ADP] ratio  
5 decreased (the effect on the ATP concentration was less than the effect on the ADP concentration as expected, see above). We also calculated the glycolytic flux through the cells with various levels of ATPase activity. We found that the flux through the glycolytic pathway was  
10 first stimulated with increasing expression of ATPase activity, until a certain (optimal) ATPase activity which gave maximal glycolytic flux. Further increase of ATPase expression resulted in a lower glycolytic flux, due to a secondary effect of the ATPase activity on the growth of  
15 the cells. This emphasizes the need for optimization of gene expression rather than merely overexpressing the genes.

#### EXAMPLE 1

20

**ATP hydrolysis and enhanced glycolytic flux in *Escherichia coli*, using an inducible promoter**

25 Restriction enzymes, T4 DNA polymerase, calf intestine phosphatase (CIP) were obtained from Pharmacia.

Procedures for DNA isolation, cutting with restriction enzymes, filling in sticky DNA ends with T4 DNA polymerase in the presence of dATP, dCTP, dGTP and dTTP,  
30 treatment with calf intestine phosphatase to remove phosphate groups from 5' DNA ends and ligation of DNA fragments are carried out by standard methods as described by Maniatis et al., 1982.

### Extraction and measurement of ATP and ADP

0.9 ml of cell culture was mixed with 0.9 ml of (80 °C) phenol (equilibrated with 10 mM Tris, 1 mM EDTA pH=8) and immediately vortexed vigorously for 10 seconds. After 1 hour at room temperature the sample was vortexed again for 10 seconds and the two phases were separated by centrifugation at 14000 rpm for 15 minutes, and then residual phenol in the water phase was removed by extraction with 1 volume of chloroform. ATP and ADP concentrations were then measured, using a luciferin-luciferase ATP monitoring kit (obtained from and used as recommended by LKB, except that 3 mM of phosphoenol-pyruvate was added). [ATP] was measured first. Subsequently the ADP in the same sample was converted to ATP by adding pyruvate kinase, and [ADP] was recorded as the concomitant increase in luminescence.

### Construction of plasmids carrying combinations of the *E. coli atp* genes

The following combinations of *E. coli* genes coding for F<sub>1</sub> subunits were chosen for expressing ATPase activity in *E. coli*: 1. *atpAGDC* (subunits  $\alpha$ ,  $\gamma$ ,  $\beta$ ,  $\epsilon$ ), 2. *atpAGD* (subunits  $\alpha$ ,  $\gamma$ ,  $\beta$ ), 3. *atpDC* (subunits  $\beta$ ,  $\epsilon$ ), and 4. *atpD* (subunit  $\beta$  alone).

### Cloning of fragments carrying *atp* genes onto pUC19

The plasmid pBJC917 (von Meyenburg, K., *et al.*, 1984) which carries the entire *atp* operon was cut with

1) the restriction enzyme *DraIII*, and a 5009 bp DNA fragment containing the *atpAGDC* genes was isolated;

2) the restriction enzymes *DraIII* and *Tth1111*, and a 4106 bp DNA fragment containing the *atpAGD* genes was isolated;

3) the restriction enzymes *DraIII* and *SacII*, and a 2364 bp DNA fragment containing the *atpDC* genes was isolated;

4) the restriction enzymes *AvaI* and *Tth111I*, and a 1472 bp DNA fragment containing the *atpD* gene was isolated.

In all four cases the fragments were then treated with T4 DNA polymerase to create blunt ends, and subsequently the fragments were ligated into the cloning vector pUC19 (Yanisch-Perron et al., 1985) which had been cut with *SmaI* and treated with CIP.

The four ligation mixtures were transformed into the *E. coli* strain JM105 (Yanisch-Perron et al., 1985), and the transformation mixtures were plated on LB (Luria-Bertani broth; Maniatis et al., 1982) plates containing 100 µg/ml ampicillin and 75 µg/ml 5-bromo-4-chloro-3-indolyl-β-D-galactoside (X-gal). In this strain background (JM105), plasmids formed by religation of pUC19 will give blue colonies, whereas plasmids that carry foreign DNA fragments inserted into the *SmaI* site of pUC19, will give white colonies. A number of white colonies from the four transformations were therefore picked for further analysis: plasmid DNA was isolated and analysed by cutting with various restriction enzymes. Clones were identified from each of the four series which had the desired fragment inserted into the *SmaI* site of pUC19, and in the proper orientation. These four plasmids were named, respectively: pATP-AGDC, pATP-AGD, pATP-DC and pATP-D, with reference to the specific *atp* genes carried by the plasmid.

#### Cloning combinations of the *atp* genes under the control of an inducible (*tac*) promoter

In order to be able to control the expression of the ATPase activity, we selected the expression vector pTTQ18



(Starck, 1987). This vector is a derivative of pUC18 (Yanisch-Perron et al., 1985), which carries a *tac* promoter and the lactose repressor gene, *lacI*. Immediately downstream of the *tac* promoter is a multiple cloning site (MCS; the polylinker from pUC18) in which genes can be inserted to be expressed from the *tac* promoter. The *tac* promoter is of the *lac*-type, i.e. repressed by the lactose repressor and inducible with isopropyl- $\beta$ -D-thiogalactoside (IPTG).

The four plasmids, pATP-AGDC, pATP-AGD, pATP-DC and pATP-D were cut with *KpnI* and *XbaI*, which gave the four DNA fragments, 5023, 4120, 2378 and 1486 respectively. After purification, the fragments were ligated into the cloning vector, pTTQ18, which had also been cut with *KpnI* and *XbaI* (see figure 1). The ligation mixtures were transformed into *E. coli* K-12 MC1000 (Casabadan and Cohen, 1980), and the transformation mixtures were plated on LB plates containing 100  $\mu$ g/ml ampicillin. A number of colonies from the four transformations were therefore picked for further analysis: plasmid DNA was isolated and analysed by cutting with various restriction enzymes. Clones were identified from each of the four series which had the desired fragment inserted into the MCS of pTTQ18 in the proper orientation. These four plasmids were named, respectively: pTAC-AGDC, pTAC-AGD, pTAC-DC and pTAC-D, with reference to the specific *atp* genes carried by these plasmid and the *tac* promoter used for their expression. For the purpose of subsequent physiological studies, the plasmids were transformed into the *E. coli* K-12 strain LM3118, which is used routinely for physiological experiments in this laboratory. The corresponding names for the LM3118 strain carrying these four plasmids are PJ4332, PJ4333, PJ4335 and PJ4334, respectively.

35

### Effect of induction of ATPase activity on the growth of *E. coli* on plates

The strains containing the four plasmids were streaked on LB plates containing ampicillin (100 µg/ml) and 1 mM of IPTG which should give maximum expression from the *tac* promoter. Table I shows how the four strains responded: the strain carrying plasmid pATP-AGDC, which contains the genes for the four subunits,  $\alpha$ ,  $\gamma$ ,  $\beta$  and  $\epsilon$ , was only very slightly affected in growth, even in the presence of 1 mM IPTG. The other three plasmids, pTAC-AGD, pTAC-DC and pTAC-D caused severe growth inhibition in the presence of 1 mM IPTG, where colonies were no longer visible. With intermediate concentrations of IPTG, 0.01 mM and 0.1 mM, the plasmids affected the growth of their host cells to different extents: pTAC-AGD was the most active, giving rise to a strong inhibition of growth already with 0.01 mM IPTG, a concentration which gave only a slight inhibition with the plasmid pTAC-DC and no inhibition of the strain with pTAC-D. With 0.1 mM IPTG, colonies were hardly visible for the strain that carried the pTAC-AGD, the plasmid pTAC-DC caused strong growth inhibition, whereas the effect of pTAC-D was significant but small.

Table I

Strain	Plasmid	- IPTG	0.01 mM IPTG	0.1 mM IPTG	1 mM IPTG
PJ4332	pTAC AGDC	++++	++++	++++	+++
PJ4333	pTAC-AGD	++++	++	+	-
PJ4335	pTAC-DC	++++	+++	+	-
PJ4334	pTAC-D	++++	++++	++	-

++++ = normal colony size; +++ = slight inhibition; ++ = 1/2 normal size; + = 1/10 normal size; - = no growth

The effect of ATPase expression from the four plasmids above was also studied in the *E. coli* mutant LM3115, in which the entire *atp* operon on the chromosome is deleted, but which grows with almost wild-type growth rate on LB

medium. With this strain transformed with the four plasmids we observed a similar pattern of growth inhibition on LB plates as a function of IPTG concentration. This shows that the effect of ATPase expression was independent of the presence of the normal *atp* operon.

#### Effect of induction of ATPase activity on the growth of *E. coli* in liquid cultures

The effect of induction of ATPase was also studied with cells grown in liquid cultures. For this purpose we chose the strain PJ4333, carrying the plasmid pTAC-AGD, because this plasmid appears to be the most active with respect to the inhibitory effect on the growth of *E. coli*. Figure 2 shows the growth of PJ4333 in minimal medium supplemented with a limiting concentration of glucose (0.4 g/l) and ampicillin (0.1 g/l), without IPTG and in the presence of increasing concentrations of IPTG. We observed that the growth rate of the strain was practically constant (within some 10%) with increasing amounts of IPTG up to about 30  $\mu$ M. At higher than 40  $\mu$ M IPTG, the growth of the cells were slightly inhibited, in accordance with the experiments on plates, see above.

However, what was affected was the final density of cells that one obtains from the limited amount of glucose that was included in each culture: The more ATPase that is expressed in the cells, the lower the yield of cell mass. Apparently, the cells become less economic with respect to converting the glucose into biomass, or in other words *they consume more glucose per cell synthesized*. If this is due to the expression of ATPase activity, then we would expect to see an effect hereof on the energy state of the cells. We therefore measured the concentrations of ATP and ADP in the cells growing with different expression levels of ATPase activity.

Indeed, the intracellular ATP concentration decreased gradually and the ADP concentration increased, with increased expression of ATPase; therefore the  $[ATP]/[ADP]$  ratio decreased with increased expression of ATPase, which imply that the increased glucose consumption is the result of increased ATP conversion to ADP, see figure 3. The actual flux of glucose through the cells ( $J_{gluc}$ , mmol glucose / g cell dry weight / hour) is also interesting, because this value tells us whether the performance of the cell increased as the ATPase activity increased.  $J_{gluc}$  can be calculated from the yield,  $Y$  (g cell dry weight / mol glucose) and the specific growth rate of the culture,  $\mu$  (1/hours):

$$J_{gluc} = \mu/Y$$

Figure 4 shows how the flux of glucose changed as the activity of ATPase increased: the glycolytic flux increased gradually as the ATPase expression increased, until a maximum was reached (at 30  $\mu M$  IPTG). Further increase of ATPase expression had a slightly negative effect on the glucose flux. This was probably because the energy state of the cells became so low that this had a negative effect on some anabolic reactions, since the growth rate was lower for the culture that was grown in the presence of 40  $\mu M$  IPTG.

The expression of subunits of the  $F_1$  part of the bacterial  $H^+$ -ATPase lowers the energy state of the bacterial cell. This is due to hydrolysis of ATP into ADP and  $P_i$ . The expression of ATPase activity does not affect the growth rate of *E. coli* much at low levels of expression, but the efficiency by which the substrate is converted into biomass was strongly reduced. Under the set of conditions used here, the expression of ATPase activity has a stimulatory effect on the rate by which the cells consumes the exogenous glucose.

## EXAMPLE 2

Expression of F<sub>1</sub>-ATPase activity from constitutive promoters in *E. coli*

5 In example 1 we used a *lac*-type promoter system to modulate the expression of the F<sub>1</sub> ATPase subunits in *E. coli*. However, for the optimization of gene expression for instance in industrial bioreactors or for the use in fermented food products, the use of *lac* type promoters is not always feasible. In this example we illustrate the optimization of F<sub>1</sub>-ATPase expression in *E. coli*, using a series of constitutive promoters of different strength, to control the expression of the *atpAGD* genes which here originates from *E. coli*. The constitutive promoters (CP promoters) were selected from a library of artificial promoters which had previously been cloned onto a shuttle vector for *E. coli* and *L. lactis*, pAK80 (Israelsen *et al.*, 1995) as described in our co-pending PCT patent application PCT/DK97/00342. The selected plasmid derivatives of pAK80 were pCP34, pCP41 and CP44 (CPX cloning vectors). The *atpAGD* fragment from pTAC-AGD (from example 1) was first subcloned in a polylinker in order to have the *atpAGD* fragment flanked by two *Bam*HI sites. Subsequently, this *Bam*HI fragment was cloned into the unique *Bam*HI site downstream of the CP promoters on the plasmids pCP34, pCP41 and CP44, resulting in the plasmids, pCP34::*atpAGD*, pCP34::*2atpAGD*, pCP41::*atpAGD* and CP44::*atpAGD*, where pCP34::*2atpAGD* contains two *atpAGD* fragments in tandem.

Subsequently, the strains were characterized with respect to growth rate, growth yield and glycolytic flux in glucose minimal medium supplemented with 200 µg/ml erythromycin, essentially as described in example 1, see table 2.

The expression of the F<sub>1</sub>-ATPase subunits had a slightly negative effect on the growth rate as the expression level increased. The effect on growth yield was much stronger and at the highest expression level the growth yield had  
 5 dropped to 40 % of the initial value. The glycolytic flux was stimulated 70% at the highest expression level of ATPase, and at this expression level the growth rate was lowered by 30%.

**Table 2.** Effect of expression of uncoupled F<sub>1</sub>-ATPase activity (*E. coli*  $\alpha$ ,  $\gamma$ ,  $\beta$  subunits) in *E. coli*

Plasmid	Biomass yield gdw/mmol glucose	Growth rate, $\mu$ h <sup>-1</sup>	Glucose flux mmol glu cose/h/gdw	Biomass yield .	Growth rate .	Glucose flux
pCP41	0,067	0,47	6,9	100	100	100
pCP41::atpAGD	0,047	0,42	9,1	69	90	131
pCP34	0,063	0,41	6,6	100	100	100
pCP34::atpAGD	0,034	0,34	9,9	54	81	149
pCP44	0,067	0,44	6,5	100	100	100
pCP44::atpAGD	0,027	0,30	11,2	40	69	170

### EXAMPLE 3

Expression of *E. coli* F<sub>1</sub>-ATPase activity from constitu-  
 5 tive promoters in *L. lactis*.

The plasmids from example 2 which express the *E. coli* F<sub>1</sub>-ATPase subunits to various extent are also capable of replicating in *L. lactis*, and could therefore be used to  
 10 test whether the *E. coli* F<sub>1</sub>-ATPase subunits can be used to hydrolyse ATP in *L. lactis*.

The plasmids pCP34::atpAGD, pCP34::2atpAGD and pCP41::atpAGD, were transformed into the *L. lactis* subspecies *cremoris* strain, MG1363, which is used routinely for physiological experiments in this laboratory. In addition we transformed the respective vectors, pCP34 and pCP41 in order to have proper control strains. Subsequently, the resulting transformants were characterized with respect to growth rate, growth yield and glycolytic flux, in comparison to the respective vectors, pCP34 and pCP41, by growing the various cultures in defined medium (SA medium) supplemented with a limiting concentration of glucose (0.1%), see table 3.

Table 3. Expression of *E. coli* F<sub>1</sub>-ATPase in *L. lactis*

Plasmid	Biomass yield gdw/mmol glucose	Growth rate, $\mu$ h <sup>-1</sup>	Glucose flux mmol glu- cose/h/gdw	Biomass yield %	Growth rate	Glucose flux
pCP34	0,073	0,664	9,161	100	100	100
pCP34::atpAGD	0,071	0,653	9,230	97,5	98,3	100,8
pCP34::2atpAGD	0,069	0,655	9,560	94,6	98,7	104,4
pCP41	0,072	0,645	8,925	100	100	100
pCP41::atpAGD	0,070	0,590	8,461	96,5	91,5	94,7

The results show that the plasmids pCP34::atpAGD and pCP34::2atpAGD did affect the growth yield and the glycolytic flux to some extent, but the plasmids were far less efficient in *L. lactis*, compared to *E. coli*. This was probably a consequence of a lower expression of the *E. coli* ATPase subunits, or some of these, in *L. lactis*, due to a lower copy number of the pAK80 vector in *L. lactis* (5-10), and due to differences in the translational efficiency of the three individual atp genes which originates from *E. coli*. The plasmid pCP41::atpAGD also resulted in a lower growth yield, indicating that also in

this case uncoupled ATP hydrolysis was taking place. However, the pCP41::atpAGD plasmid had a relatively strong inhibitory effect on the growth rate and therefore the glycolytic flux was not increased by this plasmid. It is possible that the heterologous expression of *E. coli* ATPase subunits resulted in growth inhibition due to effects other than ATP hydrolysis, e.g. by interfering with the function of the *L. lactis* F<sub>1</sub>F<sub>0</sub> H<sup>+</sup>-ATPase complex.

#### 10 EXAMPLE 4

Expression of *L. lactis* F<sub>1</sub>-ATPase subunits  $\beta$  and  $\epsilon$ , in *L. lactis*.

15 In the example above we showed that the expression of F<sub>1</sub>-ATPase subunits from *E. coli* in *L. lactis*, resulted in only a small stimulation of the glycolytic flux. It is possible that the heterologous expression of *E. coli* ATPase subunits resulted in growth inhibition due to effects other than ATP hydrolysis, e.g. by interfering with the function of the *L. lactis* F<sub>1</sub>F<sub>0</sub> H<sup>+</sup>-ATPase complex. In the present example we have expressed the *L. lactis* F<sub>1</sub>-ATPase subunits,  $\beta$  and  $\epsilon$ , in *L. lactis*, as this appeared to be an effective combination of subunits when expressed in *E. coli*, see example 1. The atpDC<sub>Llc</sub> genes from *L. lactis* subspecies *cremoris* (SEQ ID No. 1) was cloned on a 2.5kb HindIII fragment into the HindIII restriction site on the standard cloning vector, pBluescript, into *E. coli* K-12, strain BOE270. Subsequently, the atpDC<sub>Llc</sub> genes were cut out on a 2.5kb BamHI-SalI fragment and cloned into 5 expression vectors, pCP32, pCP34, pCP37, pCP41 and pCP44 which had been digested with BamHI and SalI, resulting in the plasmids pCP32::atpDC<sub>Llc</sub>, pCP34::atpDC<sub>Llc</sub>, pCP37::atpDC<sub>Llc</sub>, pCP41::atpDC<sub>Llc</sub> and pCP44::atpDC<sub>Llc</sub>, respectively, where the lacLM genes downstream of the CP promoters, have been replaced with the atpDC<sub>Llc</sub> genes. These plasmids should express the *L. lactis* F<sub>1</sub>-ATPase



subunits,  $\beta$  and  $\epsilon$ , to different extent. The plasmids were then transformed into MG1363 with selection for the erythromycin resistance carried by these vectors. Experiments were then performed to test whether the constructs

5 resulted in conversion of ATP into ADP in *L. lactis*. The strains carrying the different constructs was then grown in GM17 medium supplemented with 5  $\mu$ g/ml erythromycin. The plasmids did not have a strong effect on the growth rate of the cultures, which remained close to the growth

10 rate of the respective vector control plasmids. The yield of biomass, however, decreases for all the cultures by up to 17%, which shows that the cultures did indeed express uncoupled ATPase activity, see table 4.

15 Table 4. Effect of expression of *L. lactis*  $\beta$  and  $\epsilon$  subunits on acid production by *L. lactis*, at 30°C and with initial pH 6.7.

Plasmid	Biomass <sup>*</sup> OD <sub>450</sub>	Final pH <sup>*</sup>	Acid formation, relative to biomass <sup>*</sup> % of vector
pCP34	5.08	4.27	100
pCP34::atpDC11c	4.72	4.21	98.0
pCP41	4.66	4.34	100
pCP41::atpDC11c	5.21	4.24	113.5
pCP37	4.89	4.28	100
pCP37::atpDC11c	4.63	4.24	116.1
pCP32	4.86	4.34	100
pCP32::atpDC11c	3.95	4.36	116.9

20 Each value is the average of 3-4 independent cultures. The acid production was calculated from the pH change, and normalized by the biomass produced.

The GM17 growth medium used in these experiments contains a surplus of glucose (1%), and growth only stops when the

25 pH of the growth medium becomes lower than approximately pH 4.3. To some extent, this mimics the situation that the lactic acid bacteria experience during cheese and

yougurt production. In this medium, the growth yield, in terms of the final cell mass of the cultures, reflects the acid production by these cultures.

- 5 In these cultures, the expression of  $F_1$ -ATPase subunits will increase three fold at approximately OD600 equal to 1.5. This is a consequence of the three fold amplification of the plasmid copy number that has been shown to take place at this point of the growth curve. In reality,  
10 the effect of expressing the  $F_1$ -ATPase subunits may therefore be larger.

To test this hypothesis, we grew some of the strains which expressed the *L. lactis*  $F_1$ -ATPase subunits  $\beta$  and  $\epsilon$   
15 in batch cultures of GM17 medium which had been adjusted to pH 5.9, see Table 5. In addition, the temperature of the growth medium may also affect the plasmid copy number and thus the expression of the  $F_1$ -ATPase subunits. The experiments were therefore performed at 37°C.

20

**Table 5.** Effect of expression of *L. lactis*  $\beta$  and  $\epsilon$  subunits on acid production by *L. lactis*, at 37°C and with initial pH 5.9.

Plasmid	Biomass <sup>a</sup> OD <sub>600</sub>	Ffinal pH <sup>b</sup>	Acid formation, relative to biomass <sup>c</sup> * of vector
pCP34	1.24	4.95	100
pCP34::atpDC <sub>11</sub>	1.06	4.87	141.4
pCP37	1.00	4.96	100
pCP37::atpDC <sub>11</sub>	0.58	4.92	188.4

25

Clearly, the effect of the  $F_1$ -ATPase activity was much stronger under these growth conditions: the amount of acid produced was almost doubled for the strain carrying the plasmid pCP37::atpDC<sub>11</sub>.

30

## EXAMPLE 5

Expression of the F<sub>1</sub>-ATPase subunits,  $\alpha$ ,  $\gamma$ , and  $\beta$ , from  
*L. lactis* subspecies *cremoris* in *L. lactis* subspecies  
5 *cremoris*.

In example 4, only the *L. lactis* F<sub>1</sub>-ATPase  $\beta$  and  $\epsilon$   
subunits were expressed in *L. lactis*. However, from the  
experiments with *E. coli* (example 1), we know that the  
10 simultaneous expression of subunits  $\alpha$ ,  $\gamma$ , and  $\beta$ , is a  
more powerful combination, which could also be the case  
for *L. lactis*. In order to obtain the same strong stimu-  
lation of the glycolytic flux and acid production in *L.*  
*lactis*, a set of vectors similar to the vectors described  
15 in example 4 was constructed, in which the *atpAGD<sub>Llc</sub>*  
genes derived from *L. lactis*, encoding the subunits  $\alpha$ ,  $\gamma$ ,  
and  $\beta$  (SEQ ID No. 1) was expressed from CP promoters with  
different activities. The *atpAGD<sub>Llc</sub>* genes from *L. lactis*  
was cloned on a 2.5 kb *Bam*HI-*Sal*I fragment into the 5  
20 vectors, pCP32, pCP34, pCP37, pCP41 and pCP44, resulting  
in the plasmids, pCP32::*atpAGD<sub>Llc</sub>*, pCP34::*atpAGD<sub>Llc</sub>*,  
pCP37::*atpAGD<sub>Llc</sub>*, pCP41::*atpAGD<sub>Llc</sub>*, pCP44::*atpAGD<sub>Llc</sub>*, re-  
spectively, where the *lacLM* genes downstream of the CP  
promoters, has been replaced with the *atpAGD<sub>Llc</sub>* genes.  
25 These plasmids will express the *L. lactis* F<sub>1</sub>-ATPase  
subunits  $\alpha$ ,  $\gamma$ , and  $\beta$ , to different extent. The plasmids  
were transformed into MG1363 with selection for the  
Erythromycin resistance carried by these vectors. Experi-  
ments were then performed to show that the constructs  
30 were effective in ATP hydrolysis in *L. lactis* and to what  
extent the glycolytic flux was enhanced, by growing the  
five different constructs in GM17 medium supplemented  
with erythromycin, and measuring the growth rate, ATP and  
ADP concentrations, the yield of biomass and the rate of  
35 acid production.

## EXAMPLE 6

Expression of F<sub>1</sub>-ATPase subunits from *L. lactis* subsp *lactis*, in *L. lactis* subspecies *lactis*.

5 In the examples 3-5 above, we used the strain *L. lactis* subsp. *cremoris*, MG1363. This strain is plasmid-free and is used routinely in our laboratory as a simple model organism for our physiological studies. But strains belonging to the subspecies *lactis* are also important in cheese  
10 production. We therefore cloned and sequenced the *atpAGD<sub>L11</sub>* genes from *L. lactis* subsp. *lactis*, (SEQ ID No. 6). Subsequently, a 4.2 kb fragment harbouring the *atpAGD<sub>L11</sub>* genes was cloned into 5 vectors, pCP32, pCP34, pCP37, pCP41 and pCP44, resulting in the plasmids,  
15 pCP32::*atpAGD<sub>L11</sub>*, pCP34::*atpAGD<sub>L11</sub>*, pCP37::*atpAGD<sub>L11</sub>*, pCP41::*atpAGD<sub>L11</sub>*, pCP44::*atpAGD<sub>L11</sub>*, respectively. These plasmids were then transformed into *L. lactis* subsp. *lactis* as described in example 3. The resulting strains with  
20 different expression levels of the F<sub>1</sub>-ATPase subunits  $\alpha$ ,  $\gamma$  and  $\beta$  were then used to characterize the effect hereof on the growth yield, growth rate, glycolytic flux, and the cellular energy state of *L. lactis* subsp. *lactis*, as described in the examples 1-5.

25

## EXAMPLE 7

Expression of F<sub>1</sub>-ATPase subunits from *S. thermophilus*, ST3, in *S. thermophilus*, ST3

30

In the examples 3-6 above, we used strains of the genus *Lactococcus*. These strains are important in cheese production. As starter cultures for yogurt production, the dairy industry often uses strains of *S. thermophilus*. We  
35 therefore cloned and sequenced the *atpAGD<sub>St</sub>* genes from *S. thermophilus*, strain ST3 (SEQ ID No. 10). Subsequently, a 4.2 kb fragment harbouring the *atpAGD<sub>St</sub>* genes was cloned

into the 5 vectors, pCP32, pCP34, pCP37, pCP41 and pCP44, resulting in the plasmids, pCP32::atpAGD<sub>St</sub>, pCP34::atpAGD<sub>St</sub>, pCP37::atpAGD<sub>St</sub>, pCP41::atpAGD<sub>St</sub>, pCP44::atpAGD<sub>St</sub>, respectively. These plasmids were then transformed into *S. thermophilus* strain ST3. The resulting strains have different expression levels of the F<sub>1</sub>-ATPase subunits  $\alpha$ ,  $\gamma$ , and  $\beta$ , and were then used to characterize the effect hereof on the growth yield, growth rate, glycolytic flux, and the cellular energy state of *S. thermophilus*, as described in the previous examples.

#### EXAMPLE 8

Expression of a truncated F<sub>1</sub>-ATPase  $\beta$  subunit from *Phaffia rhodozyma* in *Saccharomyces cerevisiae*

In this example we show that uncoupled F<sub>1</sub>-ATPase expression can also be used to hydrolyze ATP in yeast cells of *Saccharomyces cerevisiae*.

A cDNA gene library was prepared from total RNA, isolated from *Phaffia rhodozyma*, by cloning the cDNA fragments into the expression vector, pYES2.0. One of the resulting plasmids, pATP $\beta$ , gave rise to an ade<sup>+</sup> phenotype in the *Saccharomyces cerevisiae* strain, W301, which carries a mutation in the ADE2 gene. Sequencing of the clone revealed a 0.9 kb insert, which encoded a protein of 254 amino acids (SEQ ID No. 14). The encoded protein had a very high homology to the C-terminal part of F<sub>1</sub>-ATPase  $\beta$  subunits from other organisms, prokaryotic as well as eukaryotic, including the  $\beta$  subunit from *S. cerevisiae* (86% identity).

The ADE2 mutation results in starvation for an intermediate further down in the purine metabolism, AICAR (which under normal conditions is produced by ADE3, two steps further down in this pathway). AICAR is essential for de

*de novo* biosynthesis of AMP and GMP, and *ADE2* mutants therefore need an alternative purine source in the growth medium. However, there is an alternative route for synthesis of AICAR which involves some of the genes involved in histidine biosynthesis. These genes are normally repressed under the conditions used for the complementation, but when the *HIS3* gene is introduced on a plasmid, this complements the *ADE2* mutation because the cells start to produce AICAR. Since AICAR is a precursor for ATP, it is likely that a lack of ATP (or increased levels of ADP and AMP) provide a signal to derepress the *HIS3* gene and generate AICAR (which will subsequently end up as ATP). Indeed, cross-pathway regulation between purine and histidine biosynthesis has been found in yeast and involves the transcription factors *BAS1* and *BAS2*. A reasonable explanation for the *ade<sup>-</sup>* phenotype conferred by the plasmid, is therefore that the plasmid gives rise to ATP hydrolysis in the cytoplasm, thereby effecting the concentrations of adenine nucleotides in the cytoplasm.

20

Importantly, this truncated  $\beta$  subunit from *Phaffia rhodozyma* that was encoded on *pATPbeta*, included the region of the  $\beta$  subunit which is thought to encode the catalytic site for ATP hydrolysis. The truncation of the N-terminal part of the  $\beta$  subunit probably means that the protein will no longer be exported into the mitochondrion, but should stay within the yeast cytoplasm.

25

The truncated  $\beta$  subunit *pATPbeta* is expressed from a *gal* promoter, i.e. it can be induced with galactose. If the truncated  $\beta$  subunit encoded by the clone is active in ATP hydrolysis it should result in a decrease in the growth yield, and at sufficiently high expression level, we should also observe inhibition of growth. The strain which expressed the truncated  $\beta$  subunit and a control strain (which contained a plasmid *pHIS3* containing a *HIS3* gene from *Phaffia rhodozyma*), were streaked on plates

35

containing galactose as the energy source, which will give maximal expression of the truncated  $\beta$  subunit. Indeed, the growth of the strain which expressed the truncated  $\beta$  subunit was strongly inhibited by the presence of galactose, whereas the control strain grew normally. As a control, the growth of the two strains were also compared on a plate containing glucose as the energy source, conditions under which the expression of the  $\beta$  subunit should be repressed, and indeed we observed little difference in growth of the two strains on these plates, see table 6.

Subsequently, for the purpose of the physiological investigations, the two strains were converted into  $\text{Rho}^-$  strains (petit mutants, defective in oxidative phosphorylation) by standard treatment with ethidium bromide. The induction with galactose caused even stronger inhibition of growth in the  $\text{Rho}^-$  background, which further indicates that the cause of the growth inhibition is uncoupled ATP hydrolysis in the cytoplasm.

**Table 6.** Effect of expression of a truncated  $\text{F}_1\text{-ATPase}$   $\beta$  subunit from *Phaffia rhodozyma* in *S. cerevisiae* on SC plates

Strain/plasmid	SC-ura + glucose	SC-ura + galactose
$\text{Rho}^+/\text{pATP}\beta$	+++++	+
$\text{Rho}^+/\text{pHIS3}$	++++	+++
$\text{Rho}^-/\text{pATP}\beta$	+++++	-
$\text{Rho}^-/\text{pHIS3}$	++++	+++

Growth experiments were performed to measure the resulting changes in the ATP/ADP ratio and the degree of stimulation of the glycolytic flux and ethanol formation, essentially as described in the examples above, and to show that the truncated  $\beta$  subunit from *Phaffia rhodozyma* is active with respect to converting ATP into ADP in the yeast cell.

## EXAMPLE 9.

Expression of  $F_1$ -ATPase  $\beta$  subunit from *Trichoderma reesei* in *Saccharomyces cerevisiae*.

5

In this example we show that the expression of the  $F_1$ -ATPase  $\beta$  subunit from the filamentous fungus, *Trichoderma reesei* can be used to improve the product formation of *Saccharomyces cerevisiae*.

10

The gene encoding the  $F_1$ -ATPase  $\beta$  subunit homologue from *Trichoderma reesei* was isolated from a cDNA library, inserted into a multicopy expression vector, pAJ401. DNA sequencing (SEQ ID 16) revealed that the cloned gene had  
15 very high homology to the  $\beta$  subunits from *Neurospora crassa* (91% identity), *Kluyveromyces lactis* (68%) and *Saccharomyces cerevisiae* (68%). Importantly, the first 43 amino acids in this  $\beta$  subunit, which encodes the signal for exporting the protein into the mitochondria, was homologous to the N-terminal part of the  $\beta$  subunit from  
20 *Neurospora crassa* (58% identity), but not to that of *Saccharomyces cerevisiae*. It is therefore likely that the  $\beta$  subunit from *Trichoderma reesei* will stay within the cytoplasm when expressed in *Saccharomyces cerevisiae*. This  
25 is important for the many cases where the fermentation is carried out anaerobically, because in these cases it is probably most efficient if the ATP hydrolysis takes place in the cytoplasm. Alternatively, in those cases where the  $\beta$  subunit is transported into the mitochondrion, it may  
30 be useful to genetically modify the  $\beta$  subunit so that it stays within the cytoplasm.

The gene encoding the  $F_1$ -ATPase  $\beta$  subunit homologue from *Trichoderma reesei* was expressed in *S. cerevisiae* strain  
35 VW16 (MAT  $\alpha$ , *leu2-3/112*, *ura3-52*, *trp1-289*, *his3D1*, *MAL2-8c*, *SUC2*). To test whether the presence of the *T. reesei*  $\beta$  subunit resulted in ATP hydrolysis in the cyto-



plasmid of the *Saccharomyces cerevisiae* host cells, we measured the intracellular concentrations of ATP, ADP and AMP, under various growth conditions in cultures of two strains expressing the  $\beta$  subunit (pATP $\beta$ 34 and pATP $\beta$ 44) and a strain carrying the vector plasmid, pFL60, see table 7.

**Table 7.** Effect of expression of *T. reesei*  $\beta$  subunit on ATP, ADP and AMP concentrations\* in *S. cerevisiae*

Strain	ATP	ADP	AMP	ATP/ADP ratio
	umol/gdw	umol/gdw	umol/gdw	
Aerobic exp. phase				
pATP $\beta$ 34	14.3	5.58	3.31	3.5
pATP $\beta$ 44	13.9	5.15	3.25	2.7
pVECTOR	16.6	5.47	3.43	3.0
Aerobic/stat. phase				
pATP $\beta$ 34	9.30	4.03	2.89	2.3
pATP $\beta$ 44	8.99	3.90	2.42	2.3
pVECTOR	19.5	4.62	2.87	4.2
anaerobic/stat. phase				
pATP $\beta$ 34	4.39	11.6	6.72	0.4
pATP $\beta$ 44	3.14	10.5	6.65	0.3
pVECTOR	8.84	10.2	6.37	0.9

\* according to Bergmeyer (1985)

The  $\beta$  subunit did not appear to have a significant effect on the concentrations of ATP, ADP and AMP in cells growing on glucose in the exponential growth phase. The reason is probably that the ATP concentration that the homeostatic control of ATP synthesis can here keep up with the extra drain on ATP conferred by the  $\beta$  subunit F<sub>1</sub>-ATPase activity. Indeed, the growth rate of these cultures was unaffected by the presence of the F<sub>1</sub>-ATPase activity, see table 7. But in the stationary cultures the concentration of ATP decreased significantly in the cultures expressing the  $\beta$  subunit, compared to the control. The effect was strongest in the anaerobically grown cultures where the ATP was lowered by a factor of 2-3. In these cultures, ATP must be generated through oxidative phosphorylation, (which is not even an option for the an-

aerobic cultures), and any effect of oxygenated. All hydrolysis should therefore indeed be stronger in these cells.

5 **Shake flask cultivations of cultures expressing the F<sub>1</sub>-ATPase  $\beta$  subunit homologue in *Saccharomyces cerevisiae*.**

Shake flask cultivations were performed under microaerobic/anaerobic conditions with volume ratio 1/1.25 and no  
10 agitation; with 400 ml growth media in 500 ml Erlenmeyers on magnetic stirring. The growth media contained 5 g/l of glucose and amino acids and bases according to synthetic complete medium (SC-ura+0.5%G). OD<sub>600</sub> was monitored during the cultivation (OD<sub>600</sub>=1.0 is equal to 0.3 g/l dry  
15 weight). Ethanol and glucose were measured with HPLC (Waters, Sugar-Pak or IC-Pak columns). Production of ethanol (grams of ethanol per grams of cell dry weight) is shown in Table 8.

20 **Table 8.** Effect of expression of *T. reesei*  $\beta$  subunit, on fluxes of ethanol and glucose in *S. cerevisiae*

Strain	$\mu$ h <sup>-1</sup>	J <sub>gluc</sub> g/h/gdw	J <sub>etoh</sub> g/h/gdw	J <sub>gluc</sub> relative to control	J <sub>etoh</sub> relative to control
pATP $\beta$ 34	0.40	2.811	1.190	107.7	105.6
pATP $\beta$ 44	0.40	2.750	1.187	105.3	105.3
pVECTOR control	0.39	2.611	1.127	100	100

These data show that the presence of the *T. reesei* F<sub>1</sub>-  
25 ATPase  $\beta$  subunit resulted in an increased flux of glucose, as well as ethanol, in the *Saccharomyces cerevisiae* host cells.

## REFERENCES

- Casabadan, M.J., and Cohen, S.N. (1980). *J. Mol. Biol.*, 138, 179-207.
- 5 Israelsen, H. (1995). Cloning and partial characterization of regulated promoters from *Lactococcus lactis* Tn917-lacZ integrants with the new promoter probe vector, pAK80. *Appl. Environ. Microbiol.*, 61, 2540-2547.
- 10 Maniatis, T., Fritsch, E.F., and Sambrook, J., (1982). *Molecular cloning*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
- 15 Miller, J.H., (1972). *Experiments in molecular genetics*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
- 20 Starck, M.J.R. (1987). Multicopy expression vectors carrying the *lac* repressor gene for regulated high-level expression of genes in *Escherichia coli*. *Gene* 51, 255-267.
- 25 von Meyenburg, K., Joergensen, B.B., and van Deurs, B. (1984). Physiological and morphological effects of overproduction of membrane-bound ATP synthase in *Escherichia coli* K-12. *EMBO J.* 3, 1791-1797.
- 30 Yanisch-Perron, C., Vieira, J., and Messing, J. (1985). Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. *Gene* 33, 103-109.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

## (i) APPLICANT:

- (A) NAME: Peter Ruhdal JENSEN
- (B) STREET: Soegaardsvej 19
- (C) CITY: Gentofte
- (E) COUNTRY: Denmark
- (F) POSTAL CODE (ZIP): DK-2820

- (ii) TITLE OF INVENTION: A method of improving the production of biomass or a desired product from a cell

- (iii) NUMBER OF SEQUENCES: 17

## (iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.1 (EPO)

## (vi) PRIORITY APPLICATION DATA:

- (A) APPLICATION NUMBER: DK 963/96
- (B) FILING DATE: 06-SEP-1996

## (2) INFORMATION FOR SEQ ID NO: 1:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4815 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: DNA (genomic)

- (iii) HYPOTHETICAL: NO

- (iv) ANTI SENSE: NO

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Lactococcus lactis subsp. cremoris
- (B) STRAIN: MG1363

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 26..550
- (D) OTHER INFORMATION: /codon\_start= 26  
/product= "ATPase subunit"  
/gene= "atpH"  
/standard\_name= "delta subunit of the F1 portion  
of the FO<sub>1</sub> ATPase"  
/label= delta-subunit

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 742..2241
- (D) OTHER INFORMATION: /codon\_start= 742  
/product= "ATPase subunit"  
/gene= "atpA"  
/standard\_name= "alpha subunit of the F1 portion

of the F<sub>0</sub>F<sub>1</sub> ATPase"  
 label= alpha-subunit

## (ix) FEATURES:

(A) NAME/KEY: CDS  
 (B) LOCATION:2260..3126  
 (D) OTHER INFORMATION:/codon\_start: 2260  
       product "ATPase subunit"  
       gene "atpG"  
       standard\_name "gamma subunit of the F<sub>1</sub> portion  
       of the F<sub>0</sub>F<sub>1</sub> ATPase"  
       label= gamma-subunit

## (ix) FEATURE:

(A) NAME/KEY: CDS  
 (B) LOCATION:3301..4767  
 (D) OTHER INFORMATION:/codon\_start: 3301  
       product "ATPase subunit"  
       gene "atpD"  
       standard\_name "beta subunit of the F<sub>1</sub> portion of  
       the F<sub>0</sub>F<sub>1</sub> ATPase"  
       label= beta-subunit

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

TATCTCGCTA AGTTAGGAGA ATAAG ATG ACA AAA GTA AAT TCA CAA AAA TAC	52
Met Thr Lys Val Asn Ser Gln Lys Tyr	
1 5	
AGT AAA GGT TTA CTT GAG GTC GGC CGA GAA AAA GGA CAA CTT GAA GCA	100
Ser Lys Ala Leu Leu Glu Val Ala Arg Glu Lys Gly Gln Leu Glu Ala	
10 15 20 25	
ATT CTT ACT GAA GTT AGC GAA ATG ATT CAG CTT TTC AAA GAA AAT AAC	148
Ile Leu Thr Glu Val Ser Glu Met Ile Gln Leu Phe Lys Glu Asn Asn	
30 35 40	
TTA GGT GGT TTT TTA GCA AAT GAA GTT TAT TCA TTC TGT GCT AAA TGT	196
Leu Gly Ala Phe Leu Ala Asn Glu Val Tyr Ser Phe Ser Ala Lys Ser	
45 50 55	
GAA TTG ATT GAT ACT TTG CTT CAA ACT TCA TCA GAA GTG ATG TCA AAT	244
Glu Leu Ile Asp Thr Leu Leu Gln Thr Ser Ser Glu Val Met Ser Asn	
60 65 70	
TTC CTG AAT ACT ATT CGT TCT AAT GGA CGT CTA CCT GAG CTC GGA GAA	292
Phe Leu Asn Thr Ile Arg Ser Asn Gly Arg Leu Ala Asp Leu Gly Glu	
75 80 85	
ATA CTT GAA GAA ACT AAA AAT GCA GCA GAT GAC ATG TTC AAA ATT GCT	340
Ile Leu Glu Glu Thr Lys Asn Ala Ala Asp Asp Met Phe Lys Ile Ala	
90 95 100 105	
GAC GTT GAA GTT GTT TCA AGT ATT GCA TTG TCA GAA GCT CAA ATT GAA	388
Asp Val Glu Val Val Ser Ser Ile Ala Leu Ser Glu Ala Gln Ile Glu	
110 115 120	
AAA TTT AAA GCA ATG GCT AAA TCA AAA TTT GAT TTA AAC GAA GTA ACA	436
Lys Phe Lys Ala Met Ala Lys Ser Lys Phe Asp Leu Asn Glu Val Thr	
125 130 135	

GTA ATT AAT ACA GTT AAT GAA AAA ATT CTC GGA GGA TTT ATT TTT AAA 484  
Val Ile Asn Thr Val Asn Glu Lys Ile Leu Gly Gly Phe Ile Val Asn  
140 145 150

TCT CGT GGA AAA ATT ATT GAC GCT TCA TTA AAA ACA CAA TTG GGT AAA 520  
Ser Arg Gly Lys Ile Ile Asp Ala Ser Leu Lys Thr Gln Leu Ala Lys  
155 160 165

ATC GCG GGT GAA ATC CTC TAATCAGGAT AGAAAAATT TCTTCTTTTG 580  
Ile Ala Ala Glu Ile Leu  
170 175

TTAAAAACTT AGTGGAGAAT TTTTCAAACT CAAACTGTTA AACTTTTGAA AACATGCAAA 640  
GGTAATTTTAA AAACTTGGTT ATTCAATGCTC AAAAAGTATA ACTGCAAGTTT AAAGCTAAAT 700

AGCCTTGAAC TAGTAAAAAA TTTCTAGAAG GGACATATT T TTG GCA ATT AAA 760  
Leu Ala Ile Lys  
1

GCT AAT GAA ATC AGT TCA CTG ATT AAA AAA GAA ATT GAA AAT TTT ACA 804  
Ala Asn Glu Ile Ser Ser Leu Ile Lys Lys Gln Ile Glu Asn Phe Thr  
5 10 15 20

CCA GAT TTT GAA GTT GCT GAA ACT GGT GTC GTT ACC TAT GTT GGT GAT 848  
Pro Asp Phe Glu Val Ala Glu Thr Gly Val Val Thr Tyr Val Gly Asp  
25 30 35

GGT ATC GCG CGT GCC TAT GGC CTT GAA AAT GCG ATG ACC GGT GAG CTT 892  
Gly Ile Ala Arg Ala Tyr Gly Leu Glu Asn Ala Met Ser Gly Glu Leu  
40 45 50

GTT GAG TTT TCA AAT GGT ATA CTT GGT ATG GCG CAA AAC TTG GAT GCT 948  
Val Glu Phe Ser Asn Gly Ile Leu Gly Met Ala Gln Asn Leu Asp Ala  
55 60 65

ACA GAC GTT GGT ATT ATC GTA CTT GGT GAT TTC CTC TCA ATT GGT GAA 992  
Thr Asp Val Gly Ile Ile Val Leu Gly Asp Phe Leu Ser Ile Arg Glu  
70 75 80

GGT GAC ACT GTT AAA CGT ACA GGT AAA ATC ATG GAA ATC CAA GTT GGT 1040  
Gly Asp Thr Val Lys Arg Thr Gly Lys Ile Met Glu Ile Gln Val Gly  
85 90 95 100

GAA GAA CTC ATC GGA CGT GTT GTA AAC CCA CTT GGA GAA CCC GTT GAT 1088  
Glu Glu Leu Ile Gly Arg Val Val Asn Pro Leu Gly Gln Pro Val Asp  
105 110 115

GGA CTT GGA GAA CTT AAT ACA GGT AAA ACT CGT GGA CTT GAA GGA AAA 1132  
Gly Leu Gly Glu Leu Asn Thr Gly Lys Thr Arg Pro Val Glu Ala Lys  
120 125 130

GCT CCT GGT GTT ATG CAA CGT AAA TCA GTC TCT GAG GCA TTA CAA ACT 1180  
Ala Pro Gly Val Met Gln Arg Lys Ser Val Ser Glu Pro Leu Gln Thr  
135 140 145

GGT CTT AAA GCG ATT GAT GGC CTC GTT CCA ATT GGA CGT GGA CAA CGT 1228  
Gly Leu Lys Ala Ile Asp Ala Leu Val Pro Ile Gly Arg Gly Gln Arg  
150 155 160

GAA TTA ATT ATC GGA GAC CGT CAA ACT GGT AAA ACT TCA GTC GGT ATT Glu Leu Ile Ile Gly Asp Arg Gln Thr Gly Lys Thr Ser Val Ala Ile 165 170 175 180	1381
GAT GCA ATC TTG AAC CAA AAA GGT CAA GAT ATG AAT TGT ATC TAT GTT Asp Ala Ile Leu Asn Gln Lys Gly Gln Asp Met Ile Cys Ile Tyr Val 185 190	1329
GCG ATT GGA CAA AAA GAG TCA ACA GTT CGT ACA CAA GTT GAA ACG CTC Ala Ile Gly Gln Lys Glu Ser Thr Val Arg Thr Gln Val Glu Thr Leu 200 205 210	1377
CGT AAA CTC GGT GCG ATG GAT TAT ACA ATC GTC GTA ACT GCG TCA GCT Arg Lys Leu Gly Ala Met Asp Tyr Thr Ile Val Val Thr Ala Ser Ala 215 220 225	1425
TCT CAA CCT TCT CCA CTC CTT TAC ATC GCT CTT TAC GCT GGA GGT GCA Ser Gln Pro Ser Pro Leu Leu Tyr Ile Ala Pro Tyr Ala Gly Ala Ala 230 235 240	1473
ATG GGT GAA GAA TTT ATG TAT AAC GGT AAA CAT GTC TTG GTT GTT TAT Met Gly Glu Glu Phe Met Tyr Asn Gly Lys His Val Leu Val Val Tyr 245 250 255 260	1521
GAT GAT TTA TCT AAA CAA GCG GTC GCT TAC CGT GAA CTT TCT CTC TTG Asp Asp Leu Ser Lys Gln Ala Val Ala Tyr Arg Glu Leu Ser Leu Leu 265 270 275	1569
CTC CGT CGT CCA CCA GGT CGT GAA GCA TAC CCA GGT GAC GTT TTC TAC Leu Arg Arg Pro Pro Gly Arg Glu Ala Tyr Pro Gly Asp Val Phe Tyr 280 285 290	1617
TTG CAC TCA CGT CTT TTG GAA CGT GCT GCT AAA TTG TCT GAT GAT CTT Leu His Ser Arg Leu Leu Glu Arg Ala Ala Lys Leu Ser Asp Asp Leu 295 300 305	1665
GGT GGT GGA TCA ATG ACG GGT TTG CCA TTC ATT GAA ACA CAA GCA GGT Gly Gly Gly Ser Met Thr Ala Leu Pro Phe Ile Glu Thr Gln Ala Gly 310 315 320	1713
GAT ATC TCA GCT TAT ATT CCA ACA AAC GTT ATC TCT ATT ACC GAC GGT Asp Ile Ser Ala Tyr Ile Pro Thr Asn Val Ile Ser Ile Thr Asp Gly 325 330 335 340	1761
CAA ATT TTC CTT GAA AAT GAC TTG TTC TAT TCA GGT GTA CGT CTT GCC Gln Ile Phe Leu Glu Asn Asp Leu Phe Tyr Ser Gly Val Arg Pro Ala 345 350 355	1809
APT GAT GCT GGT TCA TCA GTA TCA CGT GTT GGT GGT GCC GCA CAA ATC Ile Asp Ala Gly Ser Ser Val Ser Arg Val Gly Gly Ala Ala Gln Ile 360 365 370	1857
AAA GCC ATG AAG AAA GTA GCT GGT ACT TTG CGT CTT GAC CTT GCG TCG Lys Ala Met Lys Lys Val Ala Gly Thr Leu Arg Leu Asp Leu Ala Ser 375 380 385	1905
TTC CGT GAA CTT GAA GCC TTT ACA CAA TTT GGT TCT GAC CTT GAT GAA Phe Arg Glu Leu Glu Ala Phe Thr Gln Phe Gly Ser Asp Leu Asp Glu 390 395 400	1953
GCG ACT CAA GCA AAA TTG AAT CGT GGT CGT CGT ACC GTT GAA GTC TTG Ala Thr Gln Ala Lys Leu Asn Arg Gly Arg Arg Thr Val Glu Val Leu 405 410 415 420	2001

AAA CAA CCA TTG CAA AAA CAA TTG GGT GTT GAA AAA CAA GTT TTG ATT	2118
Lys Gln Pro Leu His Lys Pro Leu Ala Val Gln Lys Gln Val Leu Ile	
425 430 435	
CTC TAT GCA TTG ACT CAT GGT CAT GTT GAT AAT GTT CCA GTT CAT GAT	2141
Leu Tyr Ala Leu Thr His Gly His Leu Asp Asn Val Pro Val Asp Asp	
440 445 450	
GTT CTT GAT TTT GAA ACT AAA ATG TTC GAT TTC TTC GAT GCA AAT TAT	2145
Val Leu Asp Phe Glu Thr Lys Met Phe Asp Phe Phe Asp Ala Asn Tyr	
455 460 465	
GCA GAT CTC TTG AAC GTA ATT ACT GAC ACT AAA GAT TTG CCA GAA GAA	2192
Ala Asp Leu Leu Asn Val Ile Thr Asp Thr Lys Asp Leu Pro Glu Glu	
470 475 480	
GCA AAA CTT GAC GAA GCA ATT AAA GCA TTC AAA AAT ACA ACG AAT TAT	2241
Ala Lys Leu Asp Glu Ala Ile Lys Ala Phe Lys Asn Thr Thr Asn Tyr	
485 490 495 500	
TAATAAGGAG GCTAACTA ATG GGA GGT TCA GTT AAC GAA ATA AAA ACT AAG	2292
Met Gly Ala Ser Leu Asn Gln Ile Lys Thr Lys	
1 5 10	
ATT GCG TCA ACA AAG AAA ACA AGT CAA ATC ACA GGT GGT ATG CAA ATG	2340
Ile Ala Ser Thr Lys Lys Thr Ser Gln Ile Thr Gly Ala Met Gln Met	
15 20 25	
GTT TCT GCT GCT AAA CTT CAA AAA GCA GAA TCT CAC GCT AAA GCT TTT	2388
Val Ser Ala Ala Lys Leu Gln Lys Ala Glu Ser His Ala Lys Ala Phe	
30 35 40	
CAG ACT TAT GCT GAA AAA GTA CGT AAG ATT ACG ACT GAC TTA GTT TCA	2436
Gln Thr Tyr Ala Glu Lys Val Arg Lys Ile Thr Thr Asp Leu Val Ser	
45 50 55	
AGC GAT AAT GAG CCG GCC AAA AAT CCG ATG ATG APT AAA CGT GAA GTC	2484
Ser Asp Asn Glu Pro Ala Lys Asn Pro Met Met Ile Lys Arg Glu Val	
60 65 70 75	
AAG AAA ACT GGC TAT CTC GTT ATC ACA TCA GAT GGT GGG CTT GTT GGC	2532
Lys Lys Thr Gly Tyr Leu Val Ile Thr Ser Asp Arg Gly Leu Val Gly	
80 85 90	
AGT TAT AAT TCA AAT ATT TTG AAG TCT GTT ATA AGT AAT ATA CGT AAA	2580
Ser Tyr Asn Ser Asn Ile Leu Lys Ser Val Ile Ser Asn Ile Arg Lys	
95 100 105	
CGC CAC ACA AAT GAG AGT GAG TAT ACA ATA GTT GGC GTT GGT GGT ACG	2628
Arg His Thr Asn Glu Ser Glu Tyr Thr Ile Leu Ala Leu Gly Gly Thr	
110 115 120	
GGA GCG GAC TTT TTC AAA GGC CGT AAC GTC AAA GTT TCT TAT GTT GTT	2676
Gly Ala Asp Phe Phe Lys Ala Arg Asn Val Lys Val Ser Tyr Val Leu	
125 130 135	
CGC GGA CTT TCA GAT CAA CCG ACC TTT GAA GAG GTT CCG GCA ATT GTT	2724
Arg Gly Leu Ser Asp Gln Pro Thr Phe Glu Glu Val Arg Ala Ile Val	
140 145 150 155	
ACA GAA GCC GTA GAA GAA TAT CAA GCA GAA GAA TTC GAT GAA CTC TAT	2772
Thr Glu Ala Val Glu Glu Tyr Gln Ala Glu Glu Phe Asp Glu Leu Tyr	
160 165 170	



GTT TGT TAC AAC CAC CAT GTG AAC TCA TTG GTA AGT GAG GCA GGG ATG 2823  
 Val Cys Tyr Asn His His Val Asn Ser Leu Val Ser Glu Ala Arg Met  
 175 180 185

GAA AAA ATG TTA CCT ATT TCT TTT GAT GAA AAA GGT GAG GAA AAA GCA 2868  
 Glu Lys Met Leu Pro Ile Ser Phe Asp Glu Lys Gly Asp Glu Lys Ala  
 190 195 200

TCT CTT GTT ACA TTT GAA TTA GAA CCA GAT CGT GAA ACA ATC TTA AAT 2916  
 Ser Leu Val Thr Phe Glu Leu Glu Pro Asp Arg Glu Thr Ile Leu Asn  
 205 210 215

CAG TTG TTG CCG CAA TAT GCT GAA AGT ATG ATT TAT GGC TCA ATT GTT 2964  
 Gln Leu Leu Pro Gln Tyr Ala Glu Ser Met Ile Tyr Gly Ser Ile Val  
 220 225 230 235

GAT GCA AAA ACA GCA GAA CAT GCT GCA GGT ATG ACC GCA ATG GGT ACT 3012  
 Asp Ala Lys Thr Ala Glu His Ala Ala Gly Met Thr Ala Met Arg Thr  
 240 245 250

GCA ACA CAT AAT GCA CAT TCT GTC ATT AAT GAT TTA ACC ATT CAA TAT 3060  
 Ala Thr Asp Asn Ala His Ser Val Ile Asn Asp Leu Thr Ile Gln Tyr  
 255 260 265

AAC CGT GCT CGT CAA GCT TCA ATT ACG CAA GAA ATT ACG GAA ATT GTT 3108  
 Asn Arg Ala Arg Gln Ala Ser Ile Thr Gln Glu Ile Thr Glu Ile Val  
 270 275 280

GCG GGT GCT TCA GCG CTA TAATTACTGT CAAACATTAT TCTCAATGTT 3156  
 Ala Gly Ala Ser Ala Leu  
 285

ACGATTTATC AACTTGAGGA ATAAATGTTT TGTCAGTAAA GGCTTTGAAT TTTAAATACG 3216

TTTGTTCAGTA AATTTTCTACT GATTAGCTTA AAAATGAATA GAANTTCTGT TGTIAGACAG 3276

AAAATAAAAA CAGGAGGAAA AACA TTG AGT TCT GGT AAA ATT ACT CAG GTT 3327  
 Leu Ser Ser Gly Lys Ile Thr Gln Val  
 1 5

ATC GGT CCC GTC GTT GAC GTG GAA TTT GGT TCT GAT GCC AAA CTG CCT 3375  
 Ile Gly Pro Val Val Asp Val Glu Phe Gly Ser Asp Ala Lys Leu Pro  
 10 15 20 25

GAG ATT AAC AAT GCC TTG ATT GTC TAC AAA GAT GTC AAT GGT TTA AAA 3423  
 Glu Ile Asn Asn Ala Leu Ile Val Tyr Lys Asp Val Asn Gly Leu Lys  
 30 35 40

ACA AAA ATT ACT CTT GAA GTT GCT TTG GAA CTT GGT GAT GGT GCA GTT 3471  
 Thr Lys Ile Thr Leu Glu Val Ala Leu Glu Leu Gly Asp Gly Ala Val  
 45 50 55

CGT ACG ATC GCT ATG GAA TCT ACT GAT GGA TTG ACT CGT GGA CTT GAA 3519  
 Arg Thr Ile Ala Met Glu Ser Thr Asp Gly Leu Thr Arg Gly Leu Glu  
 60 65 70

GTC CTT GAT ACA GGT AAA GCG GTC AGC GTT CCT GTT GGT GAA TCT ACT 3567  
 Val Leu Asp Thr Gly Lys Ala Val Ser Val Pro Val Gly Glu Ser Thr  
 75 80 85

CTT GGT CGT GTT TTT AAT GTC CTT GGT GAG GTT ATT GAT GGT GGA GAA 3615  
 Leu Gly Arg Val Phe Asn Val Leu Gly Asp Val Ile Asp Gly Gly Glu  
 90 95 100 105

GAT	TTG	ACT	GCT	GAT	GCA	GAA	GCT	AAT	GCT	ATG	PAT	AAG	AAA	ATT	GGA	3677
Asp	Phe	Pro	Ala	Asp	Ala	Glu	Arg	Asn	Pro	Ile	His	Lys	Lys	Ala	Pro	
			115						115							
ACT	TTT	GAC	GAA	TTG	TCA	ACT	GCA	AAT	GAA	GTT	CTT	GTA	ACA	GGG	ATT	3711
Thr	Phe	Asp	Glu	Leu	Ser	Thr	Ala	Asn	Glu	Val	Leu	Val	Thr	Gly	Ile	
			125						130					135		
AAA	GTT	GTC	GAT	TTA	CTT	GCC	GCT	TAT	CTT	AAA	GGT	GGG	AAA	GTC	GGA	3759
Lys	Val	Val	Asp	Leu	Leu	Ala	Pro	Tyr	Leu	Lys	Gly	Gly	Lys	Val	Gly	
			140					145					150			
GTC	TTG	GGT	GGT	GCC	GGT	GTT	GGT	AAA	ACC	GTC	CTT	ATC	CAA	GAA	TTG	3807
Leu	Phe	Gly	Gly	Ala	Gly	Val	Gly	Lys	Thr	Val	Leu	Ile	Gln	Gln	Leu	
			155				160					165				
ATT	CAT	AAT	ATT	GTC	TAA	GAA	CAC	GGT	GGT	ATT	TCT	GTA	TTT	ACA	GGT	3855
Ile	His	Asn	Ile	Ala	Gln	Glu	His	Gly	Gly	Ile	Ser	Val	Phe	Thr	Gly	
			170			175				180					185	
GTT	GGC	GAT	GCT	ACT	GCT	GAC	GGG	AAT	GAC	CTT	TAC	TGG	GAA	ATG	AAA	3903
Val	Gly	Asp	Arg	Thr	Arg	Asp	Gly	Asn	Asp	Leu	Tyr	Trp	Glu	Met	Lys	
				190					195					200		
GAA	TCA	GGC	GTT	ATT	GAA	AAA	ACA	GCC	ATG	GTC	TTT	GGT	CAA	ATG	AAT	3951
Glu	Ser	Gly	Val	Ile	Glu	Lys	Thr	Ala	Met	Val	Phe	Gly	Gln	Met	Asn	
			205					210						215		
GAA	CCA	GCT	GGA	GCA	GCT	ATG	GCT	GTT	GCC	CTT	ACT	GGT	TTA	ACA	ATT	3999
Glu	Pro	Pro	Gly	Ala	Arg	Met	Arg	Val	Ala	Leu	Thr	Gly	Leu	Thr	Ile	
			220					225					230			
GGG	GAA	TAT	TTG	GCT	GAT	GTT	CAA	GGA	CAA	GAC	GTA	TTG	CTT	TTC	ATC	4047
Ala	Glu	Tyr	Phe	Arg	Asp	Val	Gln	Gly	Gln	Asp	Val	Leu	Leu	Phe	Ile	
			235				240					245				
GAT	AAC	ATC	TTG	GCT	TTG	ACT	CAA	GCT	GGT	TCA	GAA	GTT	TCT	GCC	GTT	4095
Asp	Asn	Ile	Phe	Arg	Phe	Thr	Gln	Ala	Gly	Ser	Glu	Val	Ser	Ala	Leu	
					255					260					265	
TGG	GGA	GCT	ATG	GCT	TCT	GCC	GTT	GGT	TAC	CAA	GCA	ACT	CTT	GCA	ACT	4143
Trp	Gly	Arg	Met	Pro	Ser	Ala	Val	Gly	Tyr	Gln	Pro	Thr	Leu	Ala	Thr	
				270					275					280		
GAA	ATG	GTT	CAA	TTA	CAG	GAA	GCT	ATC	ACT	TCT	ACT	AAG	AAG	GGT	TCT	4191
Glu	Met	Val	Gln	Leu	Gln	Glu	Arg	Ile	Thr	Ser	Thr	Lys	Lys	Gly	Ser	
			285					290						295		
GTT	ACA	TCT	ATC	CCA	GCG	ATT	TAT	GTC	GCT	GCC	GAT	GAC	TAT	ACT	GAC	4239
Val	Thr	Ser	Ile	Pro	Ala	Ile	Tyr	Val	Pro	Ala	Asp	Asp	Tyr	Thr	Asp	
			300				305						310			
CCA	GCG	TCA	GCT	ACA	GCG	TTG	GCT	CAC	TTG	GAC	GCA	ACA	ACT	AAC	TTG	4287
Pro	Ala	Pro	Ala	Thr	Ala	Phe	Ala	His	Leu	Asp	Ala	Thr	Thr	Asn	Leu	
			315				320					325				
GAA	GCT	GCT	TTG	ACA	CAA	ATG	GGT	ATC	TAT	CCA	GCC	GTT	GAC	CCA	CTT	4335
Glu	Arg	Arg	Leu	Thr	Gln	Met	Gly	Ile	Tyr	Pro	Ala	Val	Asp	Pro	Leu	
			330			335				340					345	
GCT	TCA	TCA	TCA	GCT	GCG	GTT	ACA	GCT	CAA	ATT	GTT	GGT	GAA	GAA	CAC	4383
Ala	Ser	Ser	Ser	Arg	Ala	Leu	Thr	Pro	Glu	Ile	Val	Gly	Glu	Gln	His	
				350					355						360	

TAT GAA GTT GCA ATG GAA GTT GAA CGT GTC CTT GAA CGT TAT AAA GAA 4431  
 Tyr Glu Val Ala Met Glu Val Gln Arg Val Leu Gln Arg Tyr Lys Glu  
 365 375 375  
 TTG CAA GAT ATC ATT GCC ATT CTT GGT ATG GAT GAA TTG TCA GAT GAT 4432  
 Leu Gln Asp Ile Ile Ala Ile Leu Gly Met Asp Glu Leu Ser Asp Asp  
 380 385 390  
 GAA AAA ATT CTC GTT GGA CGT GCA CGT CGT ATC CAA TTC TTC CTT TCA 4527  
 Glu Lys Ile Leu Val Gly Arg Ala Arg Arg Ile Gln Phe Phe Leu Ser  
 395 400 405  
 CAA AAC TTC CAC GTT GCT GAA CAG TTT ACT GGT CAA CCT GGT TCA TAT 4575  
 Gln Asn Phe His Val Ala Glu Gln Phe Thr Gly Gln Pro Gly Ser Tyr  
 410 415 420 425  
 GTA CCA ATT GAT AAA ACA GTT CAT GAC TTC AAG GAA ATT TTG GAA GGT 4604  
 Val Pro Ile Asp Lys Thr Val His Asp Phe Lys Glu Ile Leu Glu Gly  
 430 435 440  
 AAA TAT GAC GAA GTC CCT GAA GAT GCT TTC GGT GGA GTA GGT CCA ATT 4671  
 Lys Tyr Asp Glu Val Pro Glu Asp Ala Phe Arg Gly Val Gly Pro Ile  
 445 450 455  
 GAA GAC GTA CTT GCA AAA GCA AAA TCA ATG GGT TAT TAATTCGATT 4717  
 Glu Asp Val Leu Ala Lys Ala Lys Ser Met Gly Tyr  
 460 465  
 TCTTATGAAA TGACAAAGTG AAAATACATT ATTGAATCGC AAAATTTACT GACAATAATT 4777  
 CTGTCGTAAG TGCTCACTTT TAAGTTCTTC CGATCGTT 4815

## (2) INFORMATION FOR SEQ ID NO: 2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 175 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Met Thr Lys Val Asn Ser Gln Lys Tyr Ser Lys Ala Leu Leu Glu Val  
 1 5 10 15  
 Ala Arg Glu Lys Gly Gln Leu Glu Ala Ile Leu Thr Glu Val Ser Glu  
 20 25 30  
 Met Ile Gln Leu Phe Lys Glu Asn Asn Leu Gly Ala Phe Leu Ala Asn  
 35 40 45  
 Glu Val Tyr Ser Phe Ser Ala Lys Ser Glu Leu Ile Asp Thr Leu Leu  
 50 55 60  
 Gln Thr Ser Ser Glu Val Met Ser Asn Phe Leu Asn Thr Ile Arg Ser  
 65 70 75 80  
 Asn Gly Arg Leu Ala Asp Leu Gly Glu Ile Leu Glu Glu Thr Lys Asn  
 85 90 95  
 Ala Ala Asp Asp Met Phe Lys Ile Ala Asp Val Glu Val Val Ser Ser  
 100 105 110

Ile Ala Leu Ser Glu Ala Gln Ile Glu Lys Phe Lys Ala Met Ala Lys  
 115 120 125  
 Ser Lys Phe Asp Leu Asn Glu Val Thr Val Ile Asn Thr Val Ala Gln  
 130 135 140  
 Lys Ile Leu Gly Gly Phe Ile Val Asn Ser Arg Gly Lys Ile Ile Asp  
 145 150 155 160  
 Ala Ser Leu Lys Thr Glu Leu Ala Lys Ile Ala Ala Glu Ile Leu  
 165 170 175

## (2) INFORMATION FOR SEQ ID NO: 3:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 500 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## (iii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Leu Ala Ile Lys Ala Asn Glu Ile Ser Ser Leu Ile Lys Lys Gln Ile  
 1 5 10  
 Glu Asn Phe Thr Pro Asp Phe Glu Val Ala Glu Thr Gly Val Val Thr  
 20 25 30  
 Tyr Val Gly Asp Gly Ile Ala Arg Ala Tyr Gly Leu Glu Asn Ala Met  
 35 40 45  
 Ser Gly Glu Leu Val Glu Phe Ser Asn Gly Ile Leu Gly Met Ala Gln  
 50 55 60  
 Asn Leu Asp Ala Thr Asp Val Gly Ile Ile Val Leu Gly Asp Phe Leu  
 65 70 75 80  
 Ser Ile Arg Glu Gly Asp Thr Val Lys Arg Thr Gly Lys Ile Met Glu  
 85 90 95  
 Ile Gln Val Gly Glu Glu Leu Ile Gly Arg Val Val Asn Pro Leu Gly  
 100 105 110  
 Gln Pro Val Asp Gly Leu Gly Glu Leu Asn Thr Gly Lys Thr Arg Pro  
 115 120 125  
 Val Glu Ala Lys Ala Pro Gly Val Met Gln Arg Lys Ser Val Ser Glu  
 130 135 140  
 Pro Leu Gln Thr Gly Leu Lys Ala Ile Asp Ala Leu Val Pro Ile Gly  
 145 150 155 160  
 Arg Gly Gln Arg Glu Leu Ile Ile Gly Asp Arg Gln Thr Gly Lys Thr  
 165 170 175  
 Ser Val Ala Ile Asp Ala Ile Leu Asn Gln Lys Gly Gln Asp Met Ile  
 180 185 190  
 Cys Ile Tyr Val Ala Ile Gly Gln Lys Glu Ser Thr Val Arg Thr Gln  
 195 200 205

Val Glu Thr Leu Arg Lys Leu Gly Ala Met Asp Tyr Thr Ile Val Val  
 210 215 220  
 Thr Ala Ser Ala Ser Gln Pro Ser Pro Leu Leu Tyr Ile Ala Pro Lys  
 225 230 235 240  
 Ala Gly Ala Ala Met Gly Glu Glu Phe Met Tyr Asn Gly Lys His Val  
 245 250 255  
 Leu Val Val Tyr Asp Asp Leu Ser Lys Gln Ala Val Ala Tyr Arg Glu  
 260 265 270  
 Leu Ser Leu Leu Leu Arg Arg Pro Pro Gly Arg Glu Ala Tyr Pro Gly  
 275 280 285  
 Asp Val Phe Tyr Leu His Ser Arg Leu Leu Glu Arg Ala Ala Lys Leu  
 290 295 300  
 Ser Asp Asp Leu Gly Gly Gly Ser Met Thr Ala Leu Pro Phe Ile Glu  
 305 310 315 320  
 Thr Gln Ala Gly Asp Ile Ser Ala Tyr Ile Pro Thr Asn Val Ile Ser  
 325 330 335  
 Ile Thr Asp Gly Gln Ile Phe Leu Glu Asn Asp Leu Phe Tyr Ser Gly  
 340 345 350  
 Val Arg Pro Ala Ile Asp Ala Gly Ser Ser Val Ser Arg Val Gly Gly  
 355 360 365  
 Ala Ala Gln Ile Lys Ala Met Lys Lys Val Ala Gly Thr Leu Arg Leu  
 370 375 380  
 Asp Leu Ala Ser Phe Arg Glu Leu Glu Ala Phe Thr Gln Phe Gly Ser  
 385 390 395 400  
 Asp Leu Asp Glu Ala Thr Gln Ala Lys Leu Asn Arg Gly Arg Arg Thr  
 405 410 415  
 Val Glu Val Leu Lys Gln Pro Leu His Lys Pro Leu Ala Val Glu Lys  
 420 425 430  
 Gln Val Leu Ile Leu Tyr Ala Leu Thr His Gly His Leu Asp Asn Val  
 435 440 445  
 Pro Val Asp Asp Val Leu Asp Phe Glu Thr Lys Met Phe Asp Phe Phe  
 450 455 460  
 Asp Ala Asn Tyr Ala Asp Leu Leu Asn Val Ile Thr Asp Thr Lys Asp  
 465 470 475 480  
 Leu Pro Glu Glu Ala Lys Leu Asp Glu Ala Ile Lys Ala Phe Lys Asn  
 485 490 495  
 Thr Thr Asn Tyr  
 500

(2) INFORMATION FOR SEQ ID NO: 4:

- (1) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 500 amino acids  
 (B) TYPE: amino acid

(b) TOPOLOGY: linear

(c) MOLECULE TYPE: protein  
(X1) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

```

Met Gly Ala Ser Leu Asn Glu Ile Lys Thr Lys Ile Ala Ser Thr Lys
 1           5           10           15
Lys Thr Ser Gln Ile Thr Gly Ala Met Gln Met Val Ser Ala Ala Lys
 20           25           30
Leu Gln Lys Ala Glu Ser His Ala Lys Ala Phe Gln Thr Tyr Ala Glu
 35           40           45
Lys Val Arg Lys Ile Thr Thr Asp Leu Val Ser Ser Asp Asn Glu Pro
 50           55           60
Ala Lys Asn Pro Met Met Ile Lys Asn Glu Val Lys Lys Thr Gly Tyr
 65           70           75           80
Leu Val Ile Thr Ser Asp Arg Gly Leu Val Gly Ser Tyr Asn Ser Asn
 85           90           95
Ile Leu Lys Ser Val Ile Ser Asn Ile Arg Lys Arg His Thr Asn Glu
100           105           110
Ser Glu Tyr Thr Ile Leu Ala Leu Gly Gly Thr Gly Ala Asp Phe Phe
115           120           125
Lys Ala Arg Asn Val Lys Val Ser Tyr Val Leu Arg Gly Leu Ser Asp
130           135           140
Gln Pro Thr Phe Glu Glu Val Arg Ala Ile Val Thr Glu Ala Val Glu
145           150           155           160
Glu Tyr Gln Ala Glu Glu Phe Asp Glu Leu Tyr Val Lys Tyr Asn His
165           170           175
His Val Asn Ser Leu Val Ser Glu Ala Arg Met Glu Lys Met Leu Pro
180           185           190
Ile Ser Phe Asp Glu Lys Gly Asp Glu Lys Ala Ser Leu Val Thr Phe
195           200           205
Glu Leu Glu Pro Asp Arg Glu Thr Ile Leu Asn Gln Leu Leu Pro Gln
210           215           220
Tyr Ala Glu Ser Met Ile Tyr Gly Ser Ile Val Asp Ala Lys Thr Ala
225           230           235           240
Glu His Ala Ala Gly Met Thr Ala Met Arg Thr Ala Thr Asp Asn Ala
245           250           255
His Ser Val Ile Asn Asp Leu Thr Ile Gln Tyr Asn Arg Ala Arg Gln
260           265           270
Ala Ser Ile Thr Gln Glu Ile Thr Glu Ile Val Ala Gly Ala Ser Ala
275           280           285
Leu

```

## (12) INFORMATION FOR SEQ ID NO: 5:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 469 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

```

Leu Ser Ser Gly Lys Ile Thr Gln Val Ile Gly Pro Val Val Asp Val
 1           5           10           15
Glu Phe Gly Ser Asp Ala Lys Leu Pro Glu Ile Asn Asn Ala Leu Ile
 20           25           30
Val Tyr Lys Asp Val Asn Gly Leu Lys Thr Lys Ile Thr Leu Glu Val
 35           40           45
Ala Leu Glu Leu Gly Asp Gly Ala Val Arg Thr Ile Ala Met Glu Ser
 50           55           60
Thr Asp Gly Leu Thr Arg Gly Leu Glu Val Leu Asp Thr Gly Lys Ala
 65           70           75           80
Val Ser Val Pro Val Gly Glu Ser Thr Leu Gly Arg Val Phe Asn Val
 85           90           95
Leu Gly Asp Val Ile Asp Gly Gly Glu Asp Phe Pro Ala Asp Ala Glu
100           105           110
Arg Asn Pro Ile His Lys Lys Ala Pro Thr Phe Asp Glu Leu Ser Thr
115           120           125
Ala Asn Glu Val Leu Val Thr Gly Ile Lys Val Val Asp Leu Leu Ala
130           135           140
Pro Tyr Leu Lys Gly Gly Lys Val Gly Leu Phe Gly Gly Ala Gly Val
145           150           155           160
Gly Lys Thr Val Leu Ile Gln Glu Leu Ile His Asn Ile Ala Gln Glu
165           170           175
His Gly Gly Ile Ser Val Phe Thr Gly Val Gly Asp Arg Thr Arg Asp
180           185           190
Gly Asn Asp Leu Tyr Trp Glu Met Lys Glu Ser Gly Val Ile Glu Lys
195           200           205
Thr Ala Met Val Phe Gly Gln Met Asn Glu Pro Pro Gly Ala Arg Met
210           215           220
Arg Val Ala Leu Thr Gly Leu Thr Ile Ala Glu Tyr Phe Arg Asp Val
225           230           235           240
Gln Gly Gln Asp Val Leu Leu Phe Ile Asp Asn Ile Phe Arg Phe Thr
245           250           255
Gln Ala Gly Ser Glu Val Ser Ala Leu Trp Gly Arg Met Pro Ser Ala
260           265           270
Val Gly Tyr Gln Pro Thr Leu Ala Thr Glu Met Val Gln Leu Glu Glu
275           280           285

```

```

Arg Ile Thr Ser Thr Lys Lys Gly Ser Val Thr Ser Ile Pro Ala Ile
290                               295                               300

Tyr Val Pro Ala Asp Asp Tyr Thr Asp Pro Ala Ser Ala Thr Ala Ile
305                               310                               315                               320

Ala His Leu Asp Ala Thr Thr Asn Leu Glu Arg Arg Leu Thr Gln Met
325                               330                               335

Gly Ile Tyr Pro Ala Val Asp Pro Leu Ala Ser Ser Ser Arg Ala Leu
340                               345                               350

Thr Pro Glu Ile Val Gly Glu Glu His Tyr Glu Val Ala Met Glu Val
355                               360                               365

Gln Arg Val Leu Gln Arg Tyr Lys Glu Leu Gln Asp Ile Ile Ala Ile
370                               375                               380

Leu Gly Met Asp Glu Leu Ser Asp Asp Glu Lys Ile Leu Val Gly Arg
385                               390                               395                               400

Ala Arg Arg Ile Gln Phe Phe Leu Ser Gln Asn Phe His Val Ala Glu
405                               410                               415

Gln Phe Thr Gly Gln Pro Gly Ser Tyr Val Pro Ile Asp Lys Thr Val
420                               425                               430

His Asp Phe Lys Glu Ile Leu Glu Gly Lys Tyr Asp Gln Val Pro Glu
435                               440                               445

Asp Ala Phe Arg Gly Val Gly Pro Ile Glu Asp Val Leu Ala Lys Ala
450                               455                               460

Lys Ser Met Gly Tyr
465

```

## (2) INFORMATION FOR SEQ ID NO: 6:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2207 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (iii) HYPOTHETICAL: NO

## (iv) ANTI-SENSE: NO

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Lactococcus lactis* subsp. *lactis*

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 4..633
- (D) OTHER INFORMATION: /partial
  - /codon\_start= 4
  - /product= "ATPase subunit, partial sequence"
  - /gene= "atpA"
  - /standard\_name= "alpha subunit of the F1 portion of the F0F1 ATPase"
  - /label= alpha-subunit



## (ix) FEATURE:

(A) NAME/KEY: CDS  
 (B) LOCATION: 653..1514  
 (C) OTHER INFORMATION: /codon\_start= 611  
 /product= "ATPase subunit"  
 /gene= "atpG"  
 /standard\_name= "gamma subunit of the F1 portion  
 of the FOF1 ATPase"  
 /label= gamma-subunit

## (ix) FEATURE:

(A) NAME/KEY: CDS  
 (B) LOCATION: 1654..2205  
 (C) OTHER INFORMATION: /partial  
 /codon\_start= 1654  
 /product= "ATPase subunit, partial sequence"  
 /gene= "atpD"  
 /standard\_name= "beta subunit of the F1 portion of  
 the FOF1 ATPase"  
 /label= beta subunit

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

TGA	TTC	TAC	TTA	CAC	TCA	CGT	CTT	TTG	GAA	GGT	GCT	GCC	AAA	TTA	TCT	48
Phe	Tyr	Leu	His	Ser	Arg	Leu	Leu	Glu	Arg	Ala	Ala	Lys	Leu	Ser		
470					475					480						
GAC	TAT	CTT	GGT	GGT	GGT	TCA	ATG	ACT	GCA	CTG	CCA	TTC	ATT	GAA	ACA	96
Asp	Tyr	Leu	Gly	Gly	Gly	Ser	Met	Thr	Ala	Leu	Pro	Phe	Ile	Glu	Thr	
485					490					495					500	
CAA	GCC	GSA	GAT	ATC	TCA	GCT	TAT	ATT	GCA	ACA	AAC	GTT	ATC	TCT	ATT	144
Gln	Ala	Gly	Asp	Ile	Ser	Ala	Tyr	Ile	Ala	Thr	Asn	Val	Ile	Ser	Ile	
				505					510					515		
ACT	GAC	GGT	CAA	ATT	TTC	CTT	GAA	AAT	GAC	TTA	TTC	TAT	TCA	GGT	GTA	192
Thr	Asp	Gly	Gln	Ile	Phe	Leu	Glu	Asn	Asp	Leu	Phe	Tyr	Ser	Gly	Val	
			520					525						530		
CGT	CCT	GCC	ATC	GAT	GCT	GGT	TCT	TCA	GTT	TCT	CGG	GTT	GGT	GGT	GCT	240
Arg	Pro	Ala	Ile	Asp	Ala	Gly	Ser	Ser	Val	Ser	Arg	Val	Gly	Gly	Ala	
		535					540				545					
GCA	CAG	ATC	AAA	GCC	ATG	AAG	AAA	GTT	GCT	GGT	ACT	TTG	GGT	CTT	GAC	288
Ala	Gln	Ile	Lys	Ala	Met	Lys	Lys	Val	Ala	Gly	Thr	Leu	Arg	Leu	Asp	
		550				555					560					
CTT	GCG	TCA	TTC	CGT	GAA	CTT	GAA	GCC	TTT	ACT	CAA	TTT	GGT	TCT	GAT	336
Leu	Ala	Ser	Phe	Arg	Glu	Leu	Glu	Ala	Phe	Thr	Gln	Phe	Gly	Ser	Asp	
565				570					575						580	
CTT	GAT	GAA	GCG	ACT	CAA	GCA	AAA	TTG	AAT	CGT	GCT	CGT	CGT	ATC	GTT	384
Leu	Asp	Glu	Ala	Thr	Gln	Ala	Lys	Leu	Asn	Arg	Gly	Arg	Arg	Thr	Val	
				585					590					595		
GAA	GTT	TTG	AAG	CAA	CCA	TTG	CAC	AAA	CCA	TTG	GCT	GTT	GAA	AAA	CAA	432
Glu	Val	Leu	Lys	Gln	Pro	Leu	His	Lys	Pro	Leu	Ala	Val	Glu	Lys	Gln	
			600					605					610			
GTT	TTA	ATT	CTT	TAT	GCA	TTG	ACT	CAT	GGT	CAC	TTG	GAT	GAT	GTT	GCA	480
Val	Leu	Ile	Leu	Tyr	Ala	Leu	Thr	His	Gly	His	Leu	Asp	Asp	Val	Pro	
			615					620					625			

GTT GAT GAC GTC GTT GAT TTT GAA AAA AAT AAT GTC GGA TTC TTC GAT Val Asp Asp Val Leu Asp Phe Glu Thr Asn Asn Val Ala Phe Phe Asp 630 635 640 575

GCA AAT TAT GCA AAA CTC TTG AAC GTG ATT ACT GAA AAT AAA GAT TGT Ala Asn Tyr Ala Lys Leu Leu Asn Val Ile Thr Glu Thr Lys Asp Cys 645 650 655 660 576

CAG AAG AAG CAA AAC TCG ACG AAG CAA TTA AAG CAT TCT AAA ATA CAA Gln Lys Lys Gln Asn Ser Thr Lys Gln Leu Lys His Ser Lys Ile Gln 665 670 675 624

CGA ATT ATT AATAAGGAGG CTAATCTA ATG GGA GGT TCA ATT AAT GAA ATA Arg Ile Ile Met Gly Ala Ser Leu Asn Glu Ile 1 5 675

AAA ACT AAG ATT GCC TCA ACG AAG AAA ACA AGT CAA ATA ACT GGA GCC Lys Thr Lys Ile Ala Ser Thr Lys Lys Thr Ser Gln Ile Thr Gly Ala 10 15 20 723

ATG CAA ATG GTT TCC GCT GCG AAA GTT CAA AAA GCT GAA TCT CAT GCC Met Gln Met Val Ser Ala Ala Lys Leu Glu Lys Ala Glu Ser His Ala 25 30 35 40 771

AAA GCA TTT CAA ATT TAT GCT GAA AAA GTT GGT AAA ATT ACA ACT GAT Lys Ala Phe Gln Ile Tyr Ala Glu Lys Val Arg Lys Ile Thr Thr Asp 45 50 55 812

TTA GTT TCC TCT GAC AAA GAG CCA GCT AAG AAT CCA ATG ATG ATA GGA Leu Val Ser Ser Asp Lys Glu Pro Ala Lys Asn Pro Met Met Ile Gly 60 65 70 867

AGA GAA GTC AAA AAA ACT GGC TAT CTT GTA ATT ACT TCG GAT CGT GGA Arg Glu Val Lys Lys Thr Gly Tyr Leu Val Ile Thr Ser Asp Arg Gly 75 80 85 915

CTT GTC GGT GGC TAT AAT TCA TAT ATT TTG AAA TCT GTC ATG AAT ACT Leu Val Gly Gly Tyr Asn Ser Tyr Ile Leu Lys Ser Val Met Asn Thr 90 95 100 963

ATC CGT AAA CGT CCT GCT AAT GAA AGT GAA TAT ACT ATT CTT GCA CTT Ile Arg Lys Arg Pro Ala Asn Glu Ser Glu Tyr Thr Ile Leu Ala Leu 105 110 115 120 1011

GGC GGT ACT GGA GCA GAT TTC TTC GGA GCA AGC AAT GTT AAA AGT TTC Gly Gly Thr Gly Ala Asp Phe Phe Gly Ala Ser Asn Val Lys Ser Phe 125 130 135 1059

TTA GTC CTT TGT GGT TTT TCA GAC CAA CCA AAT TTT GAA GAA GTT AGA Leu Val Leu Cys Gly Phe Ser Asp Gln Pro Asn Phe Glu Glu Val Arg 140 145 150 1107

GCG ATT GTT ACA GAA GCG GTA ACT GAA TAT CAA GCA GAA GAA TTT GAT Ala Ile Val Thr Glu Ala Val Thr Glu Tyr Gln Ala Glu Glu Phe Asp 155 160 165 1155

GAA CTT TAT GTT TGC TAT AAT CAC CAT GTG AAC TCA TTG GTA AGT GAA Glu Leu Tyr Val Cys Tyr Asn His His Val Asn Ser Leu Val Ser Glu 170 175 180 1203

GCA AGT ATG GAA AAA ATG TTG CCT ATT TTT TTT GAA GCA TCA GGT CAA Ala Ser Met Glu Lys Met Leu Pro Ile Phe Phe Glu Ala Ser Gly Gln 185 190 195 200 1251

CAA AAA CCA TTT TTT GAA ACA TTT GAA TTA GAA CCA GAT TGT GAA ACA Gln Lys Pro Phe Phe Gln Thr Phe Glu Leu Glu Pro Asp Cys Glu Thr 205 210 215	1393
ATT TTA AAC CAA TTT TTT CCA CCA TAC GGT GAA AGT ATG ATT TAT GGT Ile Leu Asn Gln Leu Leu Pro Pro Tyr Ala Glu Ser Met Ile Tyr Gly 220 225 230	1397
TCA ATC GTT GAT GCT AAG ACA GCA GAA CAT GCT GCA GGT ATG ACA GCA Ser Ile Val Asp Ala Lys Thr Ala Glu His Ala Ala Gly Met Thr Ala 235 240 245	1395
ATG CGT ACT GCA ACT GAT AAT GCT CAC TCT GTT ATC AAT GAT TTG ACT Met Arg Thr Ala Thr Asp Asn Ala His Ser Val Ile Asn Asp Leu Thr 250 255 260	1443
ATT CAA TAC AAC CGT GCT CGT CAA GCA TCG ATT ACC CAA GAA ATT ACC Ile Gln Tyr Asn Arg Ala Arg Gln Ala Ser Ile Thr Gln Glu Ile Thr 265 270 275 280	1491
GAA ATC GTT GCA GCA GGC TCA GGC CTT TAATTTACTG ATAGGAATTC Gln Ile Val Ala Gly Ala Ser Ala Leu 285	1545
TGTCACTGAT GGGTTGGAAT CTFAATTGTT TTTGTGAGTA AAATTTTTCAC TGACAAACAT AAAAATGAAT AGAAATTCCTT TTCTTTGACA GAAAATAAAA ACAGGAGGAA AAACA TTG Leu 1	1598 1656
AGT TCT GGT AAA ATT ACT CAG ATT ATC GST CCC GTC GTT GAC GTG GAA Ser Ser Gly Lys Ile Thr Gln Ile Ile Gly Pro Val Val Asp Val Glu 5 10 15	1704
TTT GGT TCT GAT GGC AAA TTG CCT GAG ATT AAC AAT GCC TTG ATT GTC Phe Gly Ser Asp Ala Lys Leu Pro Glu Ile Asn Asn Ala Leu Ile Val 20 25 30	1752
TAC AAA GAT GTC AAT GGC CTA AAA ACA AAA ATT ACT CTT GAA GTT GCT Tyr Lys Asp Val Asn Gly Leu Lys Thr Lys Ile Thr Leu Glu Val Ala 35 40 45	1800
TTG GAA CTT GGT GAT GGT GCA GTT CGT ACA ATC GCT ATG GAA TCT ACT Leu Glu Leu Gly Asp Gly Ala Val Arg Thr Ile Ala Met Glu Ser Thr 50 55 60 65	1848
GAT GGC TTG ACT CGT GGA CTT GAA GTC CTT GAT ACA GGT AAA GCA GTC Asp Gly Leu Thr Arg Gly Leu Glu Val Leu Asp Thr Gly Lys Ala Val 70 75 80	1896
AGC GTT CCT GTT GGG GAA GGC ACT CTT GGT CGT GTT TTT AAC GTC CTT Ser Val Pro Val Gly Glu Ala Thr Leu Gly Arg Val Phe Asn Val Leu 85 90 95	1944
GGT GAT GTT ATT GAC GGT GGG GAA GAA TTT GCT GCT GAT GCA GAA CGT Gly Asp Val Ile Asp Gly Gly Glu Glu Phe Ala Ala Asp Ala Glu Arg 100 105 110	1992
AAT CCT ATC CAT AAA AAA GCT CCA ACA TTT GAC GAA TTG TCA ACT GCA Asn Pro Ile His Lys Lys Ala Pro Thr Phe Asp Glu Leu Ser Thr Ala 115 120 125	2040

AAC GAA GTT CTC GGA ACT GGG ATT AAA GTT GTT GAT TTC GTT GAA GGT 1088  
 Asn Glu Val Leu Val Thr Gly Ile Lys Val Val Asp Leu Leu Ala Pro  
 135 135 140 145  
 TAC CTT AAA GGT GGT AAA GTT GGA CTT TTC GGT GGT CTC GGA GTT GGT 1130  
 Tyr Leu Lys Gly Gly Lys Val Gly Leu Phe Gly Gly Ala Gly Val Gly  
 150 155 160  
 AAA GCC GTC CTT ATT CAA GAA TTG AAA CAC AAC ATC GCC CAA GAA CAC 1184  
 Lys Ala Val Leu Ile Gln Glu Leu Lys His Asn Ile Ala Gln Glu His  
 165 170 175  
 GGA GGT ATT TCT GTG TTT ACC GG 1230  
 Gly Gly Ile Ser Val Phe Thr  
 180

## (2) INFORMATION FOR SEQ ID NO: 7:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 210 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

Phe Tyr Leu His Ser Arg Leu Leu Glu Arg Ala Ala Lys Leu Ser Asp  
 1 5 10 15  
 Tyr Leu Gly Gly Gly Ser Met Thr Ala Leu Pro Phe Ile Glu Thr Gln  
 20 25 30  
 Ala Gly Asp Ile Ser Ala Tyr Ile Ala Thr Asn Val Ile Ser Ile Thr  
 35 40 45  
 Asp Gly Gln Ile Phe Leu Glu Asn Asp Leu Phe Tyr Ser Gly Val Arg  
 50 55 60  
 Pro Ala Ile Asp Ala Gly Ser Ser Val Ser Arg Val Gly Gly Ala Ala  
 65 70 75 80  
 Gln Ile Lys Ala Met Lys Lys Val Ala Gly Thr Leu Arg Leu Asp Leu  
 85 90 95  
 Ala Ser Phe Arg Glu Leu Glu Ala Phe Thr Gln Phe Gly Ser Asp Leu  
 100 105 110  
 Asp Glu Ala Thr Gln Ala Lys Leu Asn Arg Gly Arg Arg Thr Val Glu  
 115 120 125  
 Val Leu Lys Gln Pro Leu His Lys Pro Leu Ala Val Glu Lys Gln Val  
 130 135 140  
 Leu Ile Leu Tyr Ala Leu Thr His Gly His Leu Asp Asp Val Pro Val  
 145 150 155 160  
 Asp Asp Val Leu Asp Phe Glu Thr Asn Asn Val Arg Phe Phe Asp Ala  
 165 170 175  
 Asn Tyr Ala Lys Leu Leu Asn Val Ile Thr Glu Thr Lys Asp Lys Gln  
 180 185 190



Glu His Ala Ala Gly Met Thr Ala Met Arg Thr Ala Thr Asp Asn Ala  
 245 250 255  
 His Ser Val Ile Asn Asp Leu Thr Ile Gln Tyr Asn Asn Ala Asn Glu  
 260 265 270  
 Ala Ser Ile Thr Gln Glu Ile Thr Glu Ile Val Ala Gly Ala Ser Ala  
 275 280 285  
 Leu

## (3) INFORMATION FOR SEQ ID NO: 9:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 184 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

Leu Ser Ser Gly Lys Ile Thr Gln Ile Ile Gly Pro Val Val Asp Val  
 1 5 10 15  
 Glu Phe Gly Ser Asp Ala Lys Leu Pro Glu Ile Asn Asn Ala Leu Ile  
 20 25 30  
 Val Tyr Lys Asp Val Asn Gly Leu Lys Thr Lys Ile Thr Leu Glu Val  
 35 40 45  
 Ala Leu Glu Leu Gly Asp Gly Ala Val Arg Thr Ile Ala Met Glu Ser  
 50 55 60  
 Thr Asp Gly Leu Thr Arg Gly Leu Glu Val Leu Asp Thr Gly Lys Ala  
 65 70 75 80  
 Val Ser Val Pro Val Gly Glu Ala Thr Leu Gly Arg Val Phe Asn Val  
 85 90 95  
 Leu Gly Asp Val Ile Asp Gly Gly Glu Glu Phe Ala Ala Asp Ala Glu  
 100 105 110  
 Arg Asn Pro Ile His Lys Lys Ala Pro Thr Phe Asp Glu Leu Ser Thr  
 115 120 125  
 Ala Asn Glu Val Leu Val Thr Gly Ile Lys Val Val Asp Leu Leu Ala  
 130 135 140  
 Pro Tyr Leu Lys Gly Gly Lys Val Gly Leu Phe Gly Gly Ala Gly Val  
 145 150 155 160  
 Gly Lys Ala Val Leu Ile Gln Glu Leu Lys His Asn Ile Ala Gln Glu  
 165 170 175  
 His Gly Gly Ile Ser Val Phe Thr  
 180

## (3) INFORMATION FOR SEQ ID NO: 10:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2161 base pairs

(B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Streptococcus thermophilus  
 (B) STRAIN: ST3

(ix) FEATURE:

(A) NAME/KEY: CDS  
 (B) LOCATION:2..637  
 (D) OTHER INFORMATION:/partial  
     /codon\_start= 2  
     /product= "ATPase subunit, partial sequence"  
     /gene= "atpA"  
     /standard\_name= "alpha subunit of the F1 portion  
     of the FOF1 ATPase"  
     /label= alpha subunit

(ix) FEATURE:

(A) NAME/KEY: CDS  
 (B) LOCATION:659..1537  
 (D) OTHER INFORMATION:/codon\_start= 659  
     /product= "ATPase subunit"  
     /gene= "atpG"  
     /standard\_name= "gamma subunit of the F1 portion  
     of the FOF1 ATPase"  
     /label= gamma-subunit

(ix) FEATURE:

(A) NAME/KEY: CDS  
 (B) LOCATION:1616..2161  
 (D) OTHER INFORMATION:/partial  
     /codon\_start= 1616  
     /product= "ATPase subunit, partial sequence"  
     /gene= "atpD"  
     /standard\_name= "beta subunit of the F1 portion of  
     the FOF1 ATPase"  
     /label= beta-subunit

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

T GAT TCT CAT CTC CAU TCA CGT CTT TTG GAA CGT TCA GCT AAG CTT	46
Asp Ser His Leu His Ser Arg Leu Leu Glu Arg Ser Ala Lys Leu	
185                    190                    195	
TCA GAT GAT CTT GGT GGT GGT TCA ATG ACT GGC TTG GCA ATC ATC CAA	94
Ser Asp Asp Leu Gly Gly Gly Ser Met Thr Ala Leu Pro Ile Ile Gln	
200                    205                    210                    215	
ACA CAA GCA GGA GAT ATC TCA GCT TAT ATC GCG ACA AAC GTT ATT TCT	142
Thr Gln Ala Gly Asp Ile Ser Ala Tyr Ile Ala Thr Asn Val Ile Ser	
220                    225                    230	

ATC ACA GAT GGA CAA ATC TTC TTG CAA GAA AAT CTT TTC AAG TCA GGT Ile Thr Asp Gly Gln Ile Phe Leu Gln Glu Asn Leu Phe Asn Ser Gly 235 240 245	120
ATC CGT CCT GCG ATT GAT GGT GGT TCT TCA GTA TCA CCG GTT GGT GGT Ile Arg Pro Ala Ile Asp Ala Gly Ser Ser Val Ser Arg Val Gly Gly 250 255 260	240
TCA GCA CAA ATC AAA GCA ATG AAG AAA GTT GGT GGT AAG CTT GGT CTT Ser Ala Gln Ile Lys Ala Met Lys Lys Val Ala Gly Thr Leu Arg Leu 265 270 275	280
GAC TTG CCT TCT CAG CGT GAA CTT GAA GCG TTC ACA TAA TTC CCG TCT Asp Leu Ala Ser His Arg Glu Leu Glu Ala Phe Thr Gln Phe Gly Ser 280 285 290 295	320
GAT TTG GAT GCG GCA ACA CAA GGT AAA CTT AAT CCG GGA CGT CCG ACA Asp Leu Asp Ala Ala Thr Gln Ala Lys Leu Asn Arg Gly Arg Arg Thr 300 305 310	360
GTT GAA GTG CTT AAA CAA GCA GTT CAT AAC CCA CTT CCG GTT GAA AAA Val Glu Val Leu Lys Gln Pro Leu His Asn Pro Leu Pro Val Glu Lys 315 320 325	400
CAA GTT CTT ATT CTT TAC GCT TTG ACA CAT GCG TTC TTG GAC ACT GTT Gln Val Leu Ile Leu Tyr Ala Leu Thr His Gly Phe Leu Asp Ser Val 330 335 340	478
CCG GTT GAT CAA ATC TTG GAT TTT GAA GAA GCG CTC TAT GAC TAC TTT Pro Val Asp Gln Ile Leu Asp Phe Glu Glu Ala Leu Tyr Asp Tyr Phe 345 350 355	526
GAT AGC CAT CAT GAG GAT ATC TTT GAA ACA ATC CCG TCA ACT AAG GAT Asp Ser His His Glu Asp Ile Phe Glu Thr Ile Arg Ser Thr Lys Asp 360 365 370 375	594
CTT CCT GAA GAA GCT GTG CTT AAT GAA GGT ATC CAA GCT TTC AAA GAT Leu Pro Glu Glu Ala Val Leu Asn Glu Ala Ile Gln Ala Phe Lys Asp 380 385 390	600
CAA TCG GAA TAC AAA TAGACATAGG GAGGACAGCA T ATG GCA GCG TCT CTA Gln Ser Glu Tyr Lys Met Ala Gly Ser Leu 395 1 5	673
AGA GAA ATC AAA GCA AAA ATT GCT TCA ATT AAG CAA ACG AGT CAT ATT Arg Glu Ile Lys Ala Lys Ile Ala Ser Ile Lys Gln Thr Ser His Ile 10 15 20	721
ACA GGA GCC ATG CAA ATG GTT TCT GCT TCT AAA TTG ACA CCG TCT GAG Thr Gly Ala Met Gln Met Val Ser Ala Ser Lys Leu Thr Arg Ser Glu 25 30 35	764
CAG GCT GCT AAA GAT TTC CAA ATC TAT GCG TCA AAA ATT ACA CAG ATC Gln Ala Ala Lys Asp Phe Gln Ile Tyr Ala Ser Lys Ile Arg Gln Ile 40 45 50	817
ACA ACA GAT CTT CTA CAT TCA GAA TTG GTT AAT GGT TCT TCA AAT CCG Thr Thr Asp Leu Leu His Ser Glu Leu Val Asn Gly Ser Ser Asn Pro 55 60 65	865
ATG TTG GAT GCA CCG CCA GTT CCG AAG TCA GGG TAT ATT GTC ATT ACT Met Leu Asp Ala Arg Pro Val Arg Lys Ser Gly Tyr Ile Val Ile Thr 70 75 80 85	913



TCA GAT AAG GGA TTA GTT GGA GGA TAT AAT TCA ACC ATT CTT AAA GGT Ser Asp Lys Gly Leu Val Gly Gly Tyr Asn Ser Thr Ile Leu Lys Ala 90 95 100	101
GTC TTG GAT ATG ATT AAA CGT GAC CAT GAT TCT GAA GAT GAA TAT GCT Val Leu Asp Met Ile Lys Arg Asp His Asp Ser Glu Asp Glu Tyr Ala 105 110 115	1029
ATC ATC TCT ATT GGT GGA ACA GGT TCA GAT TTC TTC AAA GCT GGT AAC Ile Ile Ser Ile Gly Gly Thr Gly Ser Asp Phe Phe Lys Ala Arg Asn 120 125 130	1057
ATG AAT GTT GCT TTT GAA CTT CGT GGC CTT GAA GAT CAA CCT AGT TTC Met Asn Val Ala Phe Glu Leu Arg Gly Leu Glu Asp Gln Pro Ser Phe 135 140 145	1109
GAT CAA GTC GGG GAA ATC ATT CTA AAA GCT GTA GGA ATG TAT CAA AAT Asp Gln Val Gly Glu Ile Ile Leu Lys Ala Val Gly Met Tyr Gln Asn 150 155 160 165	1153
GAG CTT TTT GAT GAA CTT TAT CTG TCT TAT AAT GAT CAT ATT AAT AGT Glu Leu Phe Asp Glu Leu Tyr Val Cys Tyr Asn His His Ile Asn Ser 170 175 180	1201
TTG TTT TGT GAA GTT TGT GTT GAA AAA ATG CTT CCA ATT GCT GAT TTT Leu Phe Cys Glu Val Cys Val Glu Lys Met Leu Pro Ile Ala Asp Phe 185 190 195	1249
GAT CCT AAT GAA TTT GAA GGC CAT GTA TTG ACC AAG TTT GAA TTG GAA Asp Pro Asn Glu Phe Glu Gly His Val Leu Thr Lys Phe Glu Leu Glu 200 205 210	1297
CCA AGT TGT GAT ACT ATT TTG GAT CAA CTT TTG CCC ACA ATA GTC GGT Pro Ser Cys Asp Thr Ile Leu Asp Gln Leu Leu Pro Thr Ile Val Gly 215 220 225	1345
GAG AGT TTT ATC TAC GGT GCT ATC GTA GAT GGC AAA ACA GCT GAG CAT Glu Ser Phe Ile Tyr Gly Ala Ile Val Asp Ala Lys Thr Ala Glu His 230 235 240 245	1393
GCT GCT GGT ATG ACC GCA ATC CAG ACT GCC ATT GAT AAT GCT AAG AAA Ala Ala Gly Met Thr Ala Met Gln Thr Ala Thr Asp Asn Ala Lys Lys 250 255 260	1441
ATA ATT AAC GAT TTA ACA ATT CAA TAC AAC GGT GCA CGT CAA GCA GCC Ile Ile Asn Asp Leu Thr Ile Gln Tyr Asn Arg Ala Arg Gln Ala Ala 265 270 275	1489
ATT ACT CAG GAA ATC ACT GAG ATT GTT GGC GGT GCT AGT GCA CTT GAA Ile Thr Gln Glu Ile Thr Glu Ile Val Gly Gly Ala Ser Ala Leu Glu 280 285 290	1537
TAGCTAGAGA TTTCTCTTGA TTTGACATAC AATAAAAAAGG GATGATTGTC ATTCAGAAAA 1547	
CTTCATAAGG AGAAAACA ATG AGC TCA GGC AAA ATT GCT CAG GTT GTT GGT Met Ser Ser Gly Lys Ile Ala Gln Val Val Gly 1 5 10	1548
CCT GTT GTA GAC GTA GCG TTT GCA ACT GGC GAT AAA CTT CCT GAG ATT Pro Val Val Asp Val Ala Phe Ala Thr Gly Asp Lys Leu Pro Glu Ile 15 20 25	1596

AAC AAT GGA TTG GTC GTT TAC ACT GAG AAG AAA AGT ATT AGA GAG ATG 44  
 Asn Asn Ala Leu Val Val Tyr Thr Glu Lys Lys Ser Leu Arg Arg Met  
 30 35 40  
 GTG CTC GAA GTA GGT TCG TTG AAA CTT GGA GAA GGT GTG GTT GGT ACC 179  
 Val Leu Glu Val Ala Ser Leu Lys Leu Gly Glu Gly Val Val Arg Thr  
 45 50 55  
 ATT GCC ATG GAA TCT ACT GAT GGA TTG ACT CGT GGG CTA GAA GTT CTG 184  
 Ile Ala Met Glu Ser Thr Asp Gly Leu Thr Arg Gly Leu Glu Val Leu  
 60 65 70 75  
 GAC ACA GGT CGT CCA ATC AGT GTT CCT GTT GGT AAA GAA CTT CTT GGA 189  
 Asp Thr Gly Arg Pro Ile Ser Val Pro Val Gly Lys Glu Leu Leu Gly  
 80 85 90  
 CGT GTC TTT AAC GTG CTT GGA GAT ACC ATT GAG ATG GAA GCA CTT TTT 193  
 Arg Val Phe Asn Val Leu Gly Asp Thr Ile Asp Met Glu Ala Pro Phe  
 95 100 105  
 GCA GAT GAT GCA GAG GGT GAA CCA ATT CAT AAA AAA GCA GGT AAT TTC 198  
 Ala Asp Asp Ala Glu Arg Glu Pro Ile His Lys Lys Ala Pro Thr Phe  
 110 115 120  
 GAT GAA TTG TCA ACA AGT ACT GAA ATC CTT GAA ACA GGG ATT AAA GTT 203  
 Asp Glu Leu Ser Thr Ser Thr Glu Ile Leu Glu Thr Gly Ile Lys Val  
 125 130 135  
 ATC GAC TTG CTT GCC CCT TAT CTT AAA GGT GGT AAA GTC GGA CTT TTC 208  
 Ile Asp Leu Leu Ala Pro Tyr Leu Lys Gly Gly Lys Val Gly Leu Phe  
 140 145 150 155  
 GGT GGT GCC GGT GTT GGT AAG GCC GTT CTT ATT CAA GAG CTG AAT CAC 212  
 Gly Gly Ala Gly Val Gly Lys Ala Val Leu Ile Gln Glu Leu Asn His  
 160 165 170  
 AAC ATT GCT CAA GAA CAC GGT GGC ATT TCC GTG 216  
 Asn Ile Ala Gln Glu His Gly Gly Ile Ser Val  
 175 180

## (2) INFORMATION FOR SEQ ID NO: 11:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 212 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

Asp Ser His Leu His Ser Arg Leu Leu Glu Arg Ser Ala Lys Leu Ser  
 1 5 10 15  
 Asp Asp Leu Gly Gly Gly Ser Met Thr Ala Leu Pro Ile Ile Gln Thr  
 20 25 30  
 Gln Ala Gly Asp Ile Ser Ala Tyr Ile Ala Thr Asn Val Ile Ser Ile  
 35 40 45  
 Thr Asp Gly Gln Ile Phe Leu Gln Glu Asn Leu Phe Asn Ser Gly Ile  
 50 55 60

Arg Pro Ala Ile Asp Ala Gly Ser Ser Val Ser Arg Val Gly Gly Ser  
 65 70 75 80  
 Ala Gln Ile Lys Ala Met Lys Lys Val Ala Gly Thr Leu Arg Leu Asp  
 85 90 95  
 Leu Ala Ser His Arg Glu Leu Glu Ala Phe Thr Gln Phe Gly Ser Asp  
 100 105 110  
 Leu Asp Ala Ala Thr Gln Ala Lys Leu Asn Arg Gly Arg Arg Thr Val  
 115 120 125  
 Glu Val Leu Lys Gln Pro Leu His Asn Pro Leu Pro Val Glu Lys Gln  
 130 135 140  
 Val Leu Ile Leu Tyr Ala Leu Thr His Gly Phe Leu Asp Ser Val Pro  
 145 150 155 160  
 Val Asp Gln Ile Leu Asp Phe Glu Glu Ala Leu Tyr Asp Tyr Phe Asp  
 165 170 175  
 Ser His His Glu Asp Ile Phe Glu Thr Ile Arg Ser Thr Lys Asp Leu  
 180 185 190  
 Pro Glu Glu Ala Val Leu Asn Glu Ala Ile Gln Ala Phe Lys Asp Gln  
 195 200 205  
 Ser Glu Tyr Lys  
 210

## (2) INFORMATION FOR SEQ ID NO: 12:

- (1) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 293 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

Met Ala Gly Ser Leu Arg Glu Ile Lys Ala Lys Ile Ala Ser Ile Lys  
 1 5 10 15  
 Gln Thr Ser His Ile Thr Gly Ala Met Gln Met Val Ser Ala Ser Lys  
 20 25 30  
 Leu Thr Arg Ser Glu Gln Ala Ala Lys Asp Phe Gln Ile Tyr Ala Ser  
 35 40 45  
 Lys Ile Arg Gln Ile Thr Thr Asp Leu Leu His Ser Glu Leu Val Asn  
 50 55 60  
 Gly Ser Ser Asn Pro Met Leu Asp Ala Arg Pro Val Arg Lys Ser Gly  
 65 70 75 80  
 Tyr Ile Val Ile Thr Ser Asp Lys Gly Leu Val Gly Gly Tyr Asn Ser  
 85 90 95  
 Thr Ile Leu Lys Ala Val Leu Asp Met Ile Lys Arg Asp His Asp Ser  
 100 105 110

Glu Asp Glu Tyr Ala Ile Ile Ser Ile Gly Gly Thr Gly Ser Asp Phe  
 115 120 125  
 Phe Lys Ala Arg Asn Met Asn Val Ala Phe Glu Leu Arg Gly Leu Glu  
 130 135 140  
 Asp Gln Pro Ser Phe Asp Gln Val Gly Glu Ile Ile Leu Lys Ala Val  
 145 150 155 160  
 Gly Met Tyr Gln Asn Glu Leu Phe Asp Glu Leu Tyr Val Cys Tyr Asn  
 165 170 175  
 His His Ile Asn Ser Leu Phe Cys Glu Val Cys Val Glu Lys Met Leu  
 180 185 190  
 Pro Ile Ala Asp Phe Asp Pro Asn Gln Phe Glu Gly His Val Leu Thr  
 195 200 205  
 Lys Phe Glu Leu Glu Pro Ser Cys Asp Thr Ile Leu Asp Gln Leu Leu  
 210 215 220  
 Pro Thr Ile Val Gly Glu Ser Phe Ile Tyr Gly Ala Ile Val Asp Ala  
 225 230 235 240  
 Lys Thr Ala Glu His Ala Ala Gly Met Thr Ala Met Gln Thr Ala Thr  
 245 250 255  
 Asp Asn Ala Lys Lys Ile Ile Asn Asp Leu Thr Ile Gln Tyr Asn Arg  
 260 265 270  
 Ala Arg Gln Ala Ala Ile Thr Gln Glu Ile Thr Glu Ile Val Gly Gly  
 275 280 285  
 Ala Ser Ala Leu Glu  
 290

## (2) INFORMATION FOR SEQ ID NO: 13:

- (1) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 182 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

Met Ser Ser Gly Lys Ile Ala Gln Val Val Gly Pro Val Val Asp Val  
 1 5 10 15  
 Ala Phe Ala Thr Gly Asp Lys Leu Pro Glu Ile Asn Asn Ala Leu Val  
 20 25 30  
 Val Tyr Thr Glu Lys Lys Ser Leu Arg Arg Met Val Leu Glu Val Ala  
 35 40 45  
 Ser Leu Lys Leu Gly Glu Gly Val Val Arg Thr Ile Ala Met Glu Ser  
 50 55 60  
 Thr Asp Gly Leu Thr Arg Gly Leu Glu Val Leu Asp Thr Gly Arg Pro  
 65 70 75 80

```

Ile Ser Val Pro Val Gly Lys Glu Leu Leu Gly Arg Val Phe Asn Val
      85                      90                      95
Leu Gly Asp Thr Ile Asp Met Glu Ala Pro Phe Ala Asp Asp Ala Glu
      100                      105                      110
Arg Glu Pro Ile His Lys Lys Ala Pro Thr Phe Asp Glu Leu Ser Thr
      115                      120                      125
Ser Thr Glu Ile Leu Glu Thr Gly Ile Lys Val Ile Asp Leu Leu Ala
      130                      135                      140
Pro Tyr Leu Lys Gly Gly Lys Val Gly Leu Phe Gly Gly Ala Gly Val
      145                      150                      155                      160
Gly Lys Ala Val Leu Ile Gln Glu Leu Asn His Asn Ile Ala Gln Glu
      165                      170                      175
His Gly Gly Ile Ser Val
      180

```

## (12) INFORMATION FOR SEQ ID NO: 14:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 914 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: C-terminal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Phaffia rhodozyma*

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 51..824
- (D) OTHER INFORMATION: /partial
  - /codon\_start= 51
  - /product= "ATPase subunit, partial sequence"
  - /gene= "ATP2"
  - /standard\_name= "beta subunit of the F1 portion of the F0F1 ATPase"
  - /label= beta subunit

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

```

GAATTCTCAA CCTTGAGGGT GACTCCAAGG TCGCTTTTGT CTTGGGACAG ATG AAC      56
                                     Met. Asn.

GAG CCC CCG GST GCT CGA GCC CGA GTC GGT TTG ACT GST TTG ACC ATC      104
Glu Pro Pro Gly Ala Arg Ala Arg Val Ala Leu Thr Gly Leu Thr Ile
185                      190                      195                      200

```

GCC GAG TAC TTC CGA GAG GAG GAA GGA CAG GAT GTC TTG CTT TTC ATC  
 Ala Glu Tyr Phe Arg Asp Glu Glu Gly Gln Asp Val Leu Leu Ile Ile  
 205 210

GAG AAC ATT TTC CGA TTC ACC CAG GGC GGT TGT GAG GTG TCT GAT TTG  
 Asp Asn Ile Phe Arg Phe Thr Gln Ala Gly Ser Glu Val Ser Ala Leu  
 220 225 230

CTT GGT CGA ATT CCC TCC GCC GTC GGA TAC CAG CCC ACT CTT TCC ACC  
 Leu Gly Arg Ile Pro Ser Ala Val Gly Tyr Gln Pro Thr Leu Ser Thr  
 235 240 245

GAT ATG GGA GGT ATG CAG GAG CGA ATT ACC ACC ACC AAG AAG GGA TCC  
 Asp Met Gly Gly Met Gln Glu Arg Ile Thr Thr Thr Lys Lys Gly Ser  
 250 255 260

ATC ACT TCC GTC CAG GCC GTC TAC GTG CCT GGT GAT GAT TTG ACC GAT  
 Ile Thr Ser Val Gln Ala Val Tyr Val Pro Ala Asp Asp Leu Thr Asp  
 265 270 275 280

CCT GCC CCC GCC ACC ACC TTC GGC CAG TTG GAG GGC ACT ACT GGT TTG  
 Pro Ala Pro Ala Thr Thr Phe Ala His Leu Asp Ala Thr Thr Val Leu  
 285 290 295

TCT CGA GGT ATC GCT GAG TTG GGT ATC TAC CCC GGT GTC GAT CCC CTT  
 Ser Arg Gly Ile Ala Glu Leu Gly Ile Tyr Pro Ala Val Asp Pro Leu  
 300 305 310

GAT TCT AAG TCC CGA ATG CTC GAC CCC CGA ATT GTC GGA CAG GAG CAC  
 Asp Ser Lys Ser Arg Met Leu Asp Pro Arg Ile Val Gly Gln Glu His  
 315 320 325

TAC GAC ATC GCC ACC AAG ACC CAG AAG ATC CTC CAG GAC TAC AAG TCC  
 Tyr Asp Ile Ala Thr Lys Thr Gln Lys Ile Leu Gln Asp Tyr Lys Ser  
 330 335 340

CTC CAG GAT ATC ATT GCC ATT CTT GGT ATG GAT GAG TTG TCT GAG GAG  
 Leu Gln Asp Ile Ile Ala Ile Leu Gly Met Asp Glu Leu Ser Glu Glu  
 345 350 355 360

GAC AAG TTG ACC GTC GAG CGA GCC CGA AAG ATC CAG CGA TTC ATG TCG  
 Asp Lys Leu Thr Val Glu Arg Ala Arg Lys Ile Gln Arg Phe Met Ser  
 365 370 375

CAG CCT TTC GCT GTC GCT CAG GTC TTC ACT GGT ATC GAG GGA AAG CTT  
 Gln Pro Phe Ala Val Ala Gln Val Phe Thr Gly Ile Glu Gly Lys Leu  
 380 385 390

GTT CCC TTG AAG ACT ACT TTG GAG TCC TTT AAG GAG CTT CTT TCC GGA  
 Val Pro Leu Lys Thr Thr Leu Glu Ser Phe Lys Glu Leu Leu Ser Gly  
 395 400 405

GCC TGC GAC CAC CTC CCT GAG TCT GCT TTC TAC ATG GTT GGT GAC ATC  
 Ala Cys Asp His Leu Pro Glu Ser Ala Phe Tyr Met Val Gly Asp Ile  
 410 415 420

GCT GAT GTC AAG GCC AAG GCT GCT GCC CAG GCT AAG GAG TTG GCT GCT  
 Ala Asp Val Lys Ala Lys Ala Ala Glu Ala Lys Glu Leu Ala Ala  
 425 430 435 440

TAAGAGAAGA GTTGTCGAAT GTGTTTCGAG GTGTCAGAST TGTCTTTTAT GAATGTTTCT  
 445

ATCTCCTTAA AAAAAAAAAA AAAAAAAAAA  
 450

## (2) INFORMATION FOR SEQ ID NO: 15:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 258 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

```

Met Asn Glu Pro Pro Gly Ala Arg Ala Arg Val Ala Leu Thr Gly Leu
 1             5             10             15

Thr Ile Ala Glu Tyr Phe Arg Asp Glu Glu Gly Gln Asp Val Leu Leu
          20             25             30

Phe Ile Asp Asn Ile Phe Arg Phe Thr Gln Ala Gly Ser Glu Val Ser
          35             40             45

Ala Leu Leu Gly Arg Ile Pro Ser Ala Val Gly Tyr Gln Pro Thr Leu
          50             55             60

Ser Thr Asp Met Gly Gly Met Gln Glu Arg Ile Thr Thr Thr Lys Lys
          65             70             75             80

Gly Ser Ile Thr Ser Val Gln Ala Val Tyr Val Pro Ala Asp Asp Leu
          85             90             95

Thr Asp Pro Ala Pro Ala Thr Thr Phe Ala His Leu Asp Ala Thr Thr
          100            105            110

Val Leu Ser Arg Gly Ile Ala Glu Leu Gly Ile Tyr Pro Ala Val Asp
          115            120            125

Pro Leu Asp Ser Lys Ser Arg Met Leu Asp Pro Arg Ile Val Gly Gln
          130            135            140

Glu His Tyr Asp Ile Ala Thr Lys Thr Gln Lys Ile Leu Gln Asp Tyr
          145            150            155            160

Lys Ser Leu Gln Asp Ile Ile Ala Ile Leu Gly Met Asp Glu Leu Ser
          165            170            175

Glu Glu Asp Lys Leu Thr Val Glu Arg Ala Arg Lys Ile Gln Arg Phe
          180            185            190

Met Ser Gln Pro Phe Ala Val Ala Gln Val Phe Thr Gly Ile Glu Gly
          195            200            205

Lys Leu Val Pro Leu Lys Thr Thr Leu Glu Ser Phe Lys Glu Leu Leu
          210            215            220

Ser Gly Ala Cys Asp His Leu Pro Glu Ser Ala Phe Tyr Met Val Gly
          225            230            235            240

Asp Ile Ala Asp Val Lys Ala Lys Ala Ala Ala Gln Ala Lys Glu Leu
          245            250            255

Ala Ala

```

## (1) INFORMATION FOR SEQ ID NO: 16:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 375 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Trichoderma reesei

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION:50..361
- (D) OTHER INFORMATION:/partial  
 /codon\_start= 50  
 /product= "ATPase subunit, partial sequence"  
 /gene= "ATP2"  
 /standard\_name= "beta subunit of F1 portion of the FOF1 ATPase"  
 /label= beta-subunit

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

```

TACTCGAAGA ATTCGGCAAG AGGCTGATTG CTCTCGTCA TCTGCCAAG ATC TTC           55
                                         Met Phe
                                         260

AAG AGC GGC GTT TCG TCC CTC GCC AGG GGT GCC CGC CCA TCA ATT ACC       103
Lys Ser Gly Val Ser Ser Leu Ala Arg Ala Ala Arg Pro Ser Ile Thr
                265                270                275

GCT CGA CGA GCT ATC CGA CCA GCC TTC CCT CGA ACC CGC CTC GCG AGG       151
Ala Arg Arg Ala Ile Arg Pro Ala Phe Pro Arg Thr Pro Leu Ala Arg
                280                285                290

CTT GCC AGC ACC CAG AGC GTC GGA GAT GGC AAG ATC CAG CAG GTC ATT       199
Leu Ala Ser Thr Gln Ser Val Gly Asp Gly Lys Ile His Gln Val Ile
                295                300                305

GGT GCC GTC GTC GAC GTC AAG TTC GAC ACC GCC AAG CTG CCT CCT ATC       247
Gly Ala Val Val Asp Val Lys Phe Asp Thr Ala Lys Leu Pro Pro Ile
                310                315                320

CTG AAC GCC CTG GAG ACC ACC AAC AAC AAC CAG AAG CTG GTC CTC GAG       295
Leu Asn Ala Leu Glu Thr Thr Asn Asn Asn Gln Lys Leu Val Leu Glu
                330                335                340

GTG GCT CAA CAC TTG GGT GAG AAT GTC GTT GGC TGC ATT GCC ATG GAC       343
Val Ala Gln His Leu Gly Glu Asn Val Val Arg Cys Ile Ala Met Asp
                345                350                355

GGA TCC GAG GGT CTC GTC GTGGTTCCAA GGCA                               375
Gly Ser Glu Gly Leu Val
                360

```

## (2) INFORMATION FOR SEQ ID NO: 17:

## (i) SEQUENCE CHARACTERISTICS:



(A) LENGTH: 104 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

Met Phe Lys Ser Gly Val Ser Ser Leu Ala Arg Ala Ala Arg Pro Ser  
1 5 10 15  
Ile Thr Ala Arg Arg Ala Ile Arg Pro Ala Phe Pro Arg Thr Pro Leu  
20 25 30  
Ala Arg Leu Ala Ser Thr Gln Ser Val Gly Asp Gly Lys Ile His Gln  
35 40 45  
Val Ile Gly Ala Val Val Asp Val Lys Phe Asp Thr Ala Lys Leu Pro  
50 55 60  
Pro Ile Leu Asn Ala Leu Glu Thr Thr Asn Asn Asn Gln Lys Leu Val  
65 70 75 80  
Leu Glu Val Ala Glu His Leu Gly Glu Asn Val Val Arg Cys Ile Ala  
85 90 95  
Met Asp Gly Ser Glu Gly Leu Val  
100

## PATENT CLAIMS

1. A method of improving the production of biomass or a desired product from a cell, characterized by expressing  
5 an uncoupled ATPase activity in said cell to induce conversion of ATP to ADP without primary effects on other cellular metabolites or functions, and incubating the cell with a suitable substrate to produce said biomass or product.
- 10 2. A method according to claim 1, characterized by expressing in said cell the soluble part ( $F_1$ ) of the membrane bound ( $F_0F_1$  type)  $H^+$ -ATPase or a portion of  $F_1$  exhibiting ATPase activity.
- 15 3. A method according to claim 1 or 2, wherein said cell is a prokaryotic cell.
- 20 4. A method according to claim 3, wherein said cell is selected from the group consisting of bacteria belonging to the genera *Lactococcus*, *Streptococcus*, *Enterococcus*, *Lactobacillus*, *Leuconostoc*, *Escherichia*, *Zymomonas*, *Bacillus* and *Pseudomonas*.
- 25 5. A method according to claim 1 or 2, wherein said cell is a eukaryotic cell.
6. A method according to claim 5, wherein said cell is a yeast cell.
- 30 7. A method according to claim 6, wherein said cell belongs to *Saccharomyces cerevisiae* or *Trichoderma reesei*.
- 35 8. A method according to any one of claims 1-7, wherein said cell is transformed or transfected with an expression vector including DNA encoding  $F_1$  or a portion thereof exhibiting ATPase activity under the control of a

promoter functioning in said cell, and said DNA is expressed in the cell.

9. A method according to claim 8, wherein said DNA encoding F<sub>1</sub> or a portion thereof is homologous to said cell.

10. A method according to claim 8, wherein said DNA encoding F<sub>1</sub> or a portion thereof is heterologous to said cell.

11. A method according to any one of claims 8-10, wherein said DNA encoding F<sub>1</sub> or a portion thereof is derived from a prokaryotic organism.

12. A method according to claim 11, wherein said DNA encoding F<sub>1</sub> or a portion thereof is derived from *Escherichia coli*, *Lactococcus lactis* or *Streptococcus thermophilus* and is selected from the group consisting of the gene encoding the F<sub>1</sub> subunit  $\beta$  or a portion thereof and various combinations of said gene or portion with the genes encoding the F<sub>1</sub> subunits  $\delta$ ,  $\alpha$ ,  $\gamma$  and  $\epsilon$  or portions thereof.

13. A method according to claim 12, wherein said DNA encoding F<sub>1</sub> or a portion thereof is selected from the group consisting of the *Escherichia coli*, *Streptococcus thermophilus* and *Lactococcus lactis* genes *atpHAGDC* (coding for subunits  $\delta$ ,  $\alpha$ ,  $\gamma$ ,  $\beta$ ,  $\epsilon$ ), *atpAGDC* (coding for subunits  $\alpha$ ,  $\gamma$ ,  $\beta$ ,  $\epsilon$ ), *atpAGD* (coding for subunits  $\alpha$ ,  $\gamma$ ,  $\beta$ ), *atpDC* (coding for subunits  $\beta$ ,  $\epsilon$ ) and *atpD* (coding for subunit  $\beta$  alone).

14. A method according to any one of claims 8-10, wherein said DNA encoding F<sub>1</sub> or a portion thereof is derived from a eukaryotic organism.

15. A method according to claim 14, wherein said DNA encoding F<sub>1</sub> or a portion thereof is derived from *Saccharomyces cerevisiae*, *Phaffia rhodozyma* or *Trichoderma reesei* and is selected from the group consisting of the gene encoding the F<sub>1</sub> subunit  $\beta$  or a portion thereof and various combinations of said gene or portion with the genes encoding the other F<sub>1</sub> subunits or portions thereof.

16. A vector including DNA encoding the soluble part (F<sub>1</sub>) of the membrane bound (F<sub>0</sub>F<sub>1</sub> type) H<sup>+</sup>-ATPase or a portion of F<sub>1</sub> exhibiting ATPase activity, said DNA being derived from *Lactococcus lactis* subsp. *cremoris* and having the sequence stated in SEQ ID No. 1.

17. A vector including DNA encoding the soluble part (F<sub>1</sub>) of the membrane bound (F<sub>0</sub>F<sub>1</sub> type) H<sup>+</sup>-ATPase or a portion of F<sub>1</sub> exhibiting ATPase activity, said DNA being derived from *Lactococcus lactis* subsp. *lactis* and having the sequence stated in SEQ ID No. 6.

18. A vector including DNA encoding the soluble part (F<sub>1</sub>) of the membrane bound (F<sub>0</sub>F<sub>1</sub> type) H<sup>+</sup>-ATPase or a portion of F<sub>1</sub> exhibiting ATPase activity, said DNA being derived from *Streptococcus thermophilus* and having the sequence stated in SEQ ID No. 10.

19. A vector including DNA encoding the soluble part (F<sub>1</sub>) of the membrane bound (F<sub>0</sub>F<sub>1</sub> type) H<sup>+</sup>-ATPase or a portion of F<sub>1</sub> exhibiting ATPase activity, said DNA being derived from *Phaffia rhodozyma* and having the sequence stated in SEQ ID No. 14.

20. A vector including DNA encoding the soluble part (F<sub>1</sub>) of the membrane bound (F<sub>0</sub>F<sub>1</sub> type) H<sup>+</sup>-ATPase or a portion of F<sub>1</sub> exhibiting ATPase activity, said DNA being derived from *Trichoderma reesei* and having the sequence stated in SEQ ID No. 16.

21. An expression vector including DNA as defined in any one of claims 16-20 under the control of a promoter capable of directing the expression of said DNA in a prokaryotic or eukaryotic cell.

5

22. A method of optimizing the formation of biomass or a desired product by a cell, **characterized** by expressing different levels of uncoupled ATPase activity in the cell, incubating the cell on a suitable substrate, measuring the conversion rate of substrate into biomass or the desired product at each level of ATPase expression, and choosing a level of ATPase expression at which the conversion rate is optimized.

15 23. A method according to claim 22, wherein a number of specimens of said cell are transformed or transfected with their respective expression vector each including DNA encoding a different portion of the cytoplasmic part (F<sub>1</sub>) of the membrane bound (F<sub>0</sub>F<sub>1</sub> type) H<sup>+</sup>-ATPase up to and including the entire F<sub>1</sub>, each portion exhibiting ATPase activity, said DNA in each expression vector being under the control of a promoter functioning in said cell, incubating each cell specimen on a suitable substrate, measuring the conversion rate of substrate into biomass or the desired product by each specimen, and choosing a specimen yielding an optimized conversion rate.

24. A method according to claim 22, wherein a number of specimens of said cell are transformed or transfected with their respective expression vector including DNA encoding a portion of the cytoplasmic part (F<sub>1</sub>) of the membrane bound (F<sub>0</sub>F<sub>1</sub> type) H<sup>+</sup>-ATPase up to and including the entire F<sub>1</sub>, said portion exhibiting ATPase activity, said DNA in the respective expression vectors being under the control of each of a series of promoters covering a broad range of promoter activities and functioning in said cell, incubating each cell specimen on a suitable sub-

strate, measuring the conversion rate of substrate into biomass or the desired product by each specimen, and choosing a specimen yielding an optimized conversion rate.

5

25. A method according to claim 24, wherein the respective expression vectors include DNA encoding different such portions of F<sub>1</sub> up to and including the entire F<sub>1</sub>, each DNA in respective expression vectors being under the control of each of a series of promoters covering a broad range of promoter activities and functioning in said cell.

26. A method according to any one of claims 23-25, wherein the promoter in each expression vector is an inducible promoter, and each cell specimen is grown at different concentrations of inducer.

27. A method according to any one of claims 23-26, wherein said DNA encoding a portion of F<sub>1</sub> up to and including the entire F<sub>1</sub> is homologous to said cell.

28. A method according to any one of claims 23-26, wherein said DNA encoding a portion of F<sub>1</sub> up to and including the entire F<sub>1</sub> is heterologous to said cell.

29. A method according to any one of claims 23-28, wherein said DNA encoding a portion of F<sub>1</sub> up to and including the entire F<sub>1</sub> is derived from a prokaryotic organism.

30. A method according to claim 29, wherein said DNA encoding a portion of F<sub>1</sub> up to and including the entire F<sub>1</sub> is derived from *Escherichia coli*, *Lactococcus lactis* or *Streptococcus thermophilus* and is selected from the group consisting of the gene encoding the F<sub>1</sub> subunit  $\beta$  or a portion thereof and various combinations of said gene or

portion with the genes encoding the F<sub>1</sub> subunits  $\delta$ ,  $\alpha$ ,  $\gamma$  and  $\epsilon$  or portions thereof.

31. A method according to claim 30, wherein said DNA encoding a portion of F<sub>1</sub> up to and including the entire F<sub>1</sub> is selected from the group consisting of the *E. coli* genes *atpAGDC* (coding for subunits  $\alpha$ ,  $\gamma$ ,  $\beta$ ,  $\epsilon$ ), *atpAGD* (coding for subunits  $\alpha$ ,  $\gamma$ ,  $\beta$ ), *atpDC* (coding for subunits  $\beta$ ,  $\epsilon$ ) and *atpD* (coding for subunit  $\beta$  alone).

10

32. A method according to any one of claims 23-28, wherein said DNA encoding a portion of F<sub>1</sub> up to and including the entire F<sub>1</sub> is derived from a eukaryotic organism.

15

33. A method according to claim 32, wherein said DNA encoding F<sub>1</sub> or a portion thereof is derived from *Saccharomyces cerevisiae*, *Phaffia rhodozyma* or *Trichoderma reesei* and is selected from the group consisting of the gene encoding the F<sub>1</sub> subunit  $\beta$  or a portion thereof and various combinations of said gene or portion with the genes encoding the other F<sub>1</sub> subunits or portions thereof.

20

Fig. 1







Fig. 2



3/4

Fig. 3





Fig. 4



1  
INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 97/00373

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C12P 1/00, C12N 15/67

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, CA, MEDLINE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 8703006 A1 (GENETICS INSTITUTE, INC.), 21 May 1987 (21.05.87), see page 7, line 3-11, page 25, line 5 - page 27, line 7	1,3-10,22
A	--	2,11-21, 23-33
A	EP 0645094 A1 (GIST-BROCADES N.V.), 29 March 1995 (29.03.95)	1-33
A	EP 0472286 A1 (MERCK & CO. INC.), 26 February 1992 (26.02.92), see claims	16-21
	--	

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

\* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "B" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

4 December 1997

Date of mailing of the international search report

11-12-1997

Name and mailing address of the ISA/  
Swedish Patent Office  
Box 5055, S-102 42 STOCKHOLM  
Facsimile No. +46 8 666 02 86

Authorized officer

Yvonne Siösteen  
Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/DK 97/00373

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 9400493 A1 (KAPoor, ARCHANA), 6 January 1994 (06.01.94), see claims  -- -----	16-21

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT  
Information on patent family members

01/10/97

International application No.

PCT/DK 97/00373

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 8703006 A1	21/05/87	AU 613307 B	01/08/91
		AU 6724687 A	02/06/87
		BR 8606980 A	03/11/87
		CA 1312567 A	12/01/93
		DE 3688743 A,T	26/08/93
		DK 350287 D	00/00/00
		EP 0245481 A,B	19/11/87
		SE 0245481 T3	
		JP 63501616 T	23/06/88
		OA 8631 A	30/11/88
		US 5268285 A	07/12/93
EP 0645094 A1	29/03/95	AU 673768 B	21/11/96
		AU 7417494 A	06/04/95
		CA 2132772 A	25/03/95
		JP 7177877 A	18/07/95
EP 0472286 A1	26/02/92	CA 2047028 A	19/01/92
		JP 5068567 A	23/03/93
WO 9400493 A1	06/01/94	AU 4651193 A	24/01/94
		EP 0649435 A	26/04/95
		JP 7508649 T	28/09/95
		US 5330754 A	19/07/94
		US 5559011 A	24/09/96

Form PCT/ISA/210 (patent family annex) (July 1992)